Details of the Drug Combinations

General Information of This Drug (ID: DMS8IFC)

Drug Name
Sorafenib   DMS8IFC
Synonyms
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Carcinoma 2A00-2F9Z Approved [1]
Clear cell renal carcinoma N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Medullary thyroid gland carcinoma N.A. Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Renal cell carcinoma 2C90 Approved [2]
Thyroid cancer 2D10 Approved [1]
Hepatocellular carcinoma 2C12.02 Phase 3 [2]
Myelodysplastic syndrome 2A37 Phase 2 [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1246 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Sorafenib DCVTWGQ 10-hydroxycamptothecin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
10-hydroxycamptothecin + Sorafenib DCX353Y 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
10-hydroxycamptothecin + Sorafenib DC554K3 10-hydroxycamptothecin Breast carcinoma (Cell Line: ZR751) [4]
10-hydroxycamptothecin + Sorafenib DCMUCGC 10-hydroxycamptothecin Breast carcinoma (Cell Line: KPL1) [4]
10-hydroxycamptothecin + Sorafenib DCY4LJ6 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [4]
10-hydroxycamptothecin + Sorafenib DC4D8JA 10-hydroxycamptothecin Carcinoma (Cell Line: OV90) [4]
10-hydroxycamptothecin + Sorafenib DCI5KPR 10-hydroxycamptothecin Colon carcinoma (Cell Line: RKO) [4]
10-hydroxycamptothecin + Sorafenib DCL5XRI 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: T-47D) [4]
10-hydroxycamptothecin + Sorafenib DC3Z4YC 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [5]
10-hydroxycamptothecin + Sorafenib DCZ9CKG 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [5]
10-hydroxycamptothecin + Sorafenib DCOXVUH 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [5]
10-hydroxycamptothecin + Sorafenib DCDFQQE 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH1650) [5]
10-hydroxycamptothecin + Sorafenib DCJMX90 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [5]
10-hydroxycamptothecin + Sorafenib DCRU7O5 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [5]
10-hydroxycamptothecin + Sorafenib DCB73FG 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [5]
10-hydroxycamptothecin + Sorafenib DCIEL8S 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [5]
10-hydroxycamptothecin + Sorafenib DC88CP6 10-hydroxycamptothecin Adenocarcinoma (Cell Line: SW-620) [5]
10-hydroxycamptothecin + Sorafenib DCJY8DY 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [5]
10-hydroxycamptothecin + Sorafenib DCAPECE 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [5]
10-hydroxycamptothecin + Sorafenib DCI6HDO 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
10-hydroxycamptothecin + Sorafenib DCX03FG 10-hydroxycamptothecin Malignant melanoma (Cell Line: A375) [5]
10-hydroxycamptothecin + Sorafenib DCDDAOX 10-hydroxycamptothecin Malignant melanoma (Cell Line: HT144) [5]
10-hydroxycamptothecin + Sorafenib DCI7O5V 10-hydroxycamptothecin Malignant melanoma (Cell Line: SKMEL30) [5]
10-hydroxycamptothecin + Sorafenib DCQBGBP 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [5]
10-hydroxycamptothecin + Sorafenib DCBC6BN 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [5]
10-hydroxycamptothecin + Sorafenib DCXZ5IX 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [5]
10-hydroxycamptothecin + Sorafenib DCMM51T 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
10-hydroxycamptothecin + Sorafenib DCMW3YK 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
10-hydroxycamptothecin + Sorafenib DCM3YKH 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [5]
ABIRATERONE + Sorafenib DCKOTAE ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
ABIRATERONE + Sorafenib DCA4OS0 ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [3]
ABIRATERONE + Sorafenib DCHB4V2 ABIRATERONE Colon carcinoma (Cell Line: KM12) [4]
Amonafide + Sorafenib DCGOKVL Amonafide Adenocarcinoma (Cell Line: DU-145) [3]
Amonafide + Sorafenib DC83V57 Amonafide Adenocarcinoma (Cell Line: A549) [3]
Amonafide + Sorafenib DC0CSP6 Amonafide Adenocarcinoma (Cell Line: HT29) [3]
Amonafide + Sorafenib DCH5MCG Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Amonafide + Sorafenib DC5Z1SB Amonafide Anaplastic large cell lymphoma (Cell Line: SR) [3]
Amonafide + Sorafenib DCMNXWZ Amonafide Astrocytoma (Cell Line: U251) [3]
Amonafide + Sorafenib DCS0VY3 Amonafide Astrocytoma (Cell Line: SNB-19) [3]
Amonafide + Sorafenib DCX83QN Amonafide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Amonafide + Sorafenib DCXM4SJ Amonafide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Amonafide + Sorafenib DCS4I51 Amonafide Malignant melanoma (Cell Line: UACC62) [3]
Amonafide + Sorafenib DCG1JI1 Amonafide Malignant melanoma (Cell Line: LOX IMVI) [3]
Amonafide + Sorafenib DC7QCIU Amonafide Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Amonafide + Sorafenib DCABJLN Amonafide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Amonafide + Sorafenib DC98MUW Amonafide Colon adenocarcinoma (Cell Line: COLO 205) [4]
Anastrozole + Sorafenib DC1959K Anastrozole Adenocarcinoma (Cell Line: DU-145) [3]
Anastrozole + Sorafenib DCGIS25 Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Anastrozole + Sorafenib DCG4001 Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Anastrozole + Sorafenib DCLMTEF Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [3]
Anastrozole + Sorafenib DCRCH6Z Anastrozole Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Anastrozole + Sorafenib DC7BGM5 Anastrozole Carcinoma (Cell Line: RXF 393) [4]
Arfolitixorin + Sorafenib DC0OG8W Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Arfolitixorin + Sorafenib DCDT43Y Arfolitixorin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Arfolitixorin + Sorafenib DCUQRT9 Arfolitixorin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Arfolitixorin + Sorafenib DCMR4BG Arfolitixorin Adenocarcinoma (Cell Line: DU-145) [5]
BIO-300 + Sorafenib DCJFR48 BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
BIO-300 + Sorafenib DC445KF BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
BIO-300 + Sorafenib DCBNLMA BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [3]
BIO-300 + Sorafenib DC9HK7Y BIO-300 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
BIO-300 + Sorafenib DCAMJU9 BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [3]
BIO-300 + Sorafenib DCBYK4Q BIO-300 Glioma (Cell Line: SF-268) [3]
BIO-300 + Sorafenib DC1SS10 BIO-300 Glioma (Cell Line: SF-295) [3]
BIO-300 + Sorafenib DCM4RJQ BIO-300 Renal cell carcinoma (Cell Line: SN12C) [3]
BIO-300 + Sorafenib DC1AWWZ BIO-300 Carcinoma (Cell Line: MCF7) [4]
BIO-300 + Sorafenib DCHFT5A BIO-300 Colon adenocarcinoma (Cell Line: COLO 205) [4]
BIO-300 + Sorafenib DC9X6AJ BIO-300 Adenocarcinoma (Cell Line: DU-145) [5]
BIO-300 + Sorafenib DCR5CSJ BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [5]
BIO-300 + Sorafenib DCBXWXZ BIO-300 Adenocarcinoma (Cell Line: A549) [5]
BIO-300 + Sorafenib DCT163G BIO-300 Adenocarcinoma (Cell Line: NCIH23) [5]
BIO-300 + Sorafenib DC1CJ3X BIO-300 Adenocarcinoma (Cell Line: HT29) [5]
BIO-300 + Sorafenib DCVZVBH BIO-300 Adenocarcinoma (Cell Line: HCC-2998) [5]
BIO-300 + Sorafenib DC0LN5S BIO-300 Adenocarcinoma (Cell Line: HCT-15) [5]
BIO-300 + Sorafenib DCHVCB8 BIO-300 Amelanotic melanoma (Cell Line: M14) [5]
BIO-300 + Sorafenib DCOS77K BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
BIO-300 + Sorafenib DCB98A5 BIO-300 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
BIO-300 + Sorafenib DC3RG73 BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [5]
BIO-300 + Sorafenib DC2UGGL BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [5]
BIO-300 + Sorafenib DC8Q8IO BIO-300 Malignant melanoma (Cell Line: UACC62) [5]
BIO-300 + Sorafenib DCX1PHR BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
BIO-300 + Sorafenib DCZ4X21 BIO-300 Prostate carcinoma (Cell Line: PC-3) [5]
Bleomycin + Sorafenib DC6AVJU Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Bleomycin + Sorafenib DCGXRC9 Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Bleomycin + Sorafenib DCU07YW Bleomycin Astrocytoma (Cell Line: SNB-19) [3]
Bleomycin + Sorafenib DCEAPP9 Bleomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Bleomycin + Sorafenib DCJGWCT Bleomycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Bleomycin + Sorafenib DCJQ6O8 Bleomycin Adenocarcinoma (Cell Line: A549) [5]
Bleomycin + Sorafenib DCGHSL4 Bleomycin Adenocarcinoma (Cell Line: HT29) [5]
Bortezomib + Sorafenib DCHWOJS Bortezomib Adenocarcinoma (Cell Line: A427) [3]
Bortezomib + Sorafenib DC90NR6 Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [3]
Bortezomib + Sorafenib DCBKZWF Bortezomib Adenocarcinoma (Cell Line: NCIH520) [3]
Bortezomib + Sorafenib DC6F7F2 Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [3]
Bortezomib + Sorafenib DCYI986 Bortezomib Adenocarcinoma (Cell Line: SW-620) [3]
Bortezomib + Sorafenib DCGV1QM Bortezomib Amelanotic melanoma (Cell Line: A2058) [3]
Bortezomib + Sorafenib DCBIHT8 Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Bortezomib + Sorafenib DCZU03K Bortezomib Germ cell tumour (Cell Line: PA1) [3]
Bortezomib + Sorafenib DC876V3 Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Bortezomib + Sorafenib DCZULYZ Bortezomib Malignant melanoma (Cell Line: A375) [3]
Bortezomib + Sorafenib DCSID7E Bortezomib Malignant melanoma (Cell Line: HT144) [3]
Bortezomib + Sorafenib DC88IIV Bortezomib Malignant melanoma (Cell Line: SKMEL30) [3]
Bortezomib + Sorafenib DCIKOHY Bortezomib Malignant melanoma (Cell Line: UACC62) [3]
Bortezomib + Sorafenib DCBWRBC Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [3]
Bortezomib + Sorafenib DCZE21S Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Bortezomib + Sorafenib DCULGX1 Bortezomib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Bortezomib + Sorafenib DCFMMCE Bortezomib Prostate carcinoma (Cell Line: LNCAP) [3]
Bortezomib + Sorafenib DCF66VG Bortezomib Breast carcinoma (Cell Line: ZR751) [4]
Bortezomib + Sorafenib DC09GZD Bortezomib Breast carcinoma (Cell Line: OCUBM) [4]
Bortezomib + Sorafenib DCD7AFQ Bortezomib Colon carcinoma (Cell Line: RKO) [4]
Bortezomib + Sorafenib DCUCMG9 Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [4]
Brincidofovir + Sorafenib DCCIIE0 Brincidofovir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Buspirone + Sorafenib DCOHOA8 Buspirone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Cabazitaxel + Sorafenib DCQP5SK Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [3]
Cabazitaxel + Sorafenib DCQJ5AA Cabazitaxel Adenocarcinoma (Cell Line: OVCAR3) [3]
Cabazitaxel + Sorafenib DCNFQU8 Cabazitaxel Adenocarcinoma (Cell Line: A549) [3]
Cabazitaxel + Sorafenib DCZC7EZ Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Cabazitaxel + Sorafenib DCQPRVQ Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [3]
Cabazitaxel + Sorafenib DC4DX0U Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [3]
Cabazitaxel + Sorafenib DCEOXW7 Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [3]
Cabazitaxel + Sorafenib DCOQT5K Cabazitaxel Adenocarcinoma (Cell Line: HT29) [3]
Cabazitaxel + Sorafenib DC1ZK0O Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [3]
Cabazitaxel + Sorafenib DCPVBSJ Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Cabazitaxel + Sorafenib DCTFCOE Cabazitaxel Amelanotic melanoma (Cell Line: M14) [3]
Cabazitaxel + Sorafenib DCZU6X0 Cabazitaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Cabazitaxel + Sorafenib DC7XRCZ Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Cabazitaxel + Sorafenib DCV2AQD Cabazitaxel Astrocytoma (Cell Line: U251) [3]
Cabazitaxel + Sorafenib DCHPFIR Cabazitaxel Astrocytoma (Cell Line: SNB-19) [3]
Cabazitaxel + Sorafenib DCQ4NSX Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Cabazitaxel + Sorafenib DCXA4PM Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cabazitaxel + Sorafenib DCTEU0Y Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Cabazitaxel + Sorafenib DCZ3YNB Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Cabazitaxel + Sorafenib DC85T2R Cabazitaxel Glioma (Cell Line: SF-268) [3]
Cabazitaxel + Sorafenib DCH9MFB Cabazitaxel Glioma (Cell Line: SF-295) [3]
Cabazitaxel + Sorafenib DCFHC83 Cabazitaxel Glioma (Cell Line: SF-539) [3]
Cabazitaxel + Sorafenib DCI4ZCU Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Cabazitaxel + Sorafenib DCHR8XA Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Cabazitaxel + Sorafenib DC2LX1O Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Cabazitaxel + Sorafenib DCR0OZP Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cabazitaxel + Sorafenib DCMSSTV Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Cabazitaxel + Sorafenib DCOP0TA Cabazitaxel Malignant melanoma (Cell Line: UACC62) [3]
Cabazitaxel + Sorafenib DCVYSFI Cabazitaxel Melanoma (Cell Line: MALME-3M) [3]
Cabazitaxel + Sorafenib DC7U0UR Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Cabazitaxel + Sorafenib DC7ASRW Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Cabazitaxel + Sorafenib DCURIWQ Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Cabazitaxel + Sorafenib DC2TTY7 Cabazitaxel Colon adenocarcinoma (Cell Line: COLO 205) [4]
Cefmenoxime + Sorafenib DCCD1AL Cefmenoxime Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Cerivastatin + Sorafenib DC7EMD7 Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Chlorzoxazone + Sorafenib DCBMMXH Chlorzoxazone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Citalopram + Sorafenib DCX0DOR Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Crizotinib + Sorafenib DCXOUAS Crizotinib Astrocytoma (Cell Line: U251) [3]
Crizotinib + Sorafenib DCYCGZ4 Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Cyclophosphamide + Sorafenib DCURLEA Cyclophosphamide Adenocarcinoma (Cell Line: OVCAR3) [3]
Cyclophosphamide + Sorafenib DCSZ9U7 Cyclophosphamide Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + Sorafenib DCZ51HE Cyclophosphamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + Sorafenib DCWQE9R Cyclophosphamide Breast carcinoma (Cell Line: ZR751) [4]
Dacarbazine + Sorafenib DC121B9 Dacarbazine Adenocarcinoma (Cell Line: HT29) [3]
Dacarbazine + Sorafenib DC7KPL1 Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Dacarbazine + Sorafenib DCSFNPL Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Dacarbazine + Sorafenib DC9K1DG Dacarbazine Glioma (Cell Line: SF-295) [3]
Dacarbazine + Sorafenib DC43SEZ Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Dacarbazine + Sorafenib DCPW4SU Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Dactinomycin + Sorafenib DCT1JEK Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Dactinomycin + Sorafenib DCQIOTJ Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Dactinomycin + Sorafenib DC9XNQP Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dactinomycin + Sorafenib DCP5V6I Dactinomycin Melanoma (Cell Line: UACC-257) [5]
Dasatinib + Sorafenib DCXSWSZ Dasatinib Adenocarcinoma (Cell Line: CAOV3) [3]
Dasatinib + Sorafenib DC9X8QK Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Dasatinib + Sorafenib DCCCU9Q Dasatinib Adenocarcinoma (Cell Line: A427) [3]
Dasatinib + Sorafenib DCQ7GXO Dasatinib Adenocarcinoma (Cell Line: NCIH1650) [3]
Dasatinib + Sorafenib DCO14B8 Dasatinib Adenocarcinoma (Cell Line: NCIH23) [3]
Dasatinib + Sorafenib DCE1S15 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [3]
Dasatinib + Sorafenib DCJEW73 Dasatinib Adenocarcinoma (Cell Line: DLD1) [3]
Dasatinib + Sorafenib DCVS3H6 Dasatinib Adenocarcinoma (Cell Line: HCT116) [3]
Dasatinib + Sorafenib DCLLEET Dasatinib Adenocarcinoma (Cell Line: HT29) [3]
Dasatinib + Sorafenib DCQNDQ8 Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
Dasatinib + Sorafenib DCMZXQH Dasatinib Amelanotic melanoma (Cell Line: A2058) [3]
Dasatinib + Sorafenib DCDEG3K Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Dasatinib + Sorafenib DC85O0I Dasatinib Germ cell tumour (Cell Line: PA1) [3]
Dasatinib + Sorafenib DCVHR6B Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Dasatinib + Sorafenib DCOB7GO Dasatinib Malignant melanoma (Cell Line: A375) [3]
Dasatinib + Sorafenib DCY3XRM Dasatinib Malignant melanoma (Cell Line: HT144) [3]
Dasatinib + Sorafenib DCSXMBR Dasatinib Malignant melanoma (Cell Line: UACC62) [3]
Dasatinib + Sorafenib DCZRRSL Dasatinib Melanoma (Cell Line: MALME-3M) [3]
Dasatinib + Sorafenib DCJ8PZK Dasatinib Mesothelioma (Cell Line: MSTO) [3]
Dasatinib + Sorafenib DCTAHEJ Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Dasatinib + Sorafenib DCSR4NY Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Dasatinib + Sorafenib DCXQRCU Dasatinib Prostate carcinoma (Cell Line: VCAP) [3]
Dasatinib + Sorafenib DCLKBFY Dasatinib Breast carcinoma (Cell Line: ZR751) [4]
Dasatinib + Sorafenib DC49JME Dasatinib Breast carcinoma (Cell Line: KPL1) [4]
Dasatinib + Sorafenib DCRJ623 Dasatinib Breast carcinoma (Cell Line: OCUBM) [4]
Dasatinib + Sorafenib DC8O8G8 Dasatinib Carcinoma (Cell Line: OV90) [4]
Dasatinib + Sorafenib DC7F6YQ Dasatinib Carcinoma (Cell Line: EFM192B) [4]
Dasatinib + Sorafenib DC21LDO Dasatinib Carcinoma (Cell Line: MDAMB436) [4]
Dasatinib + Sorafenib DCKS7GZ Dasatinib Colon adenocarcinoma (Cell Line: LOVO) [4]
Dasatinib + Sorafenib DCNT15U Dasatinib Colon carcinoma (Cell Line: RKO) [4]
Dasatinib + Sorafenib DC07SWA Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dexamethasone + Sorafenib DC37XRR Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [5]
Dexamethasone + Sorafenib DCJP280 Dexamethasone Adenocarcinoma (Cell Line: OVCAR3) [5]
Dexamethasone + Sorafenib DCGF6EQ Dexamethasone Adenocarcinoma (Cell Line: DLD1) [5]
Dexamethasone + Sorafenib DC9HZNA Dexamethasone Amelanotic melanoma (Cell Line: A2058) [5]
Dexamethasone + Sorafenib DCGXVA6 Dexamethasone Mesothelioma (Cell Line: MSTO) [5]
Dexamethasone + Sorafenib DCYE5JJ Dexamethasone Non small cell carcinoma (Cell Line: SKMES1) [5]
Dexamethasone + Sorafenib DCPPRD4 Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dexrazoxane + Sorafenib DCXUJVR Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
DFN-15 + Sorafenib DCSYGJZ DFN-15 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
DFN-15 + Sorafenib DC9DHCW DFN-15 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
DFN-15 + Sorafenib DCOADX6 DFN-15 Adenocarcinoma (Cell Line: DU-145) [5]
DFN-15 + Sorafenib DC5U7B1 DFN-15 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Digitoxin + Sorafenib DCGKJ93 Digitoxin Lung adenocarcinoma (Cell Line: EKVX) [3]
Digitoxin + Sorafenib DCZ9HN6 Digitoxin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Docetaxel + Sorafenib DCA27SC Docetaxel Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Sorafenib DCPVH4D Docetaxel Adenocarcinoma (Cell Line: A549) [3]
Docetaxel + Sorafenib DCMCT2I Docetaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Docetaxel + Sorafenib DC4N0PP Docetaxel Adenocarcinoma (Cell Line: HCT116) [3]
Docetaxel + Sorafenib DC6ZBOE Docetaxel Adenocarcinoma (Cell Line: HT29) [3]
Docetaxel + Sorafenib DCJU6GE Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [3]
Docetaxel + Sorafenib DCWWR06 Docetaxel Amelanotic melanoma (Cell Line: M14) [3]
Docetaxel + Sorafenib DCLPU1U Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Docetaxel + Sorafenib DC3R9M9 Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [3]
Docetaxel + Sorafenib DCHNR29 Docetaxel Astrocytoma (Cell Line: U251) [3]
Docetaxel + Sorafenib DCWWCJ9 Docetaxel Astrocytoma (Cell Line: SNB-19) [3]
Docetaxel + Sorafenib DCBDNZD Docetaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Docetaxel + Sorafenib DCIZRNG Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [3]
Docetaxel + Sorafenib DC5NA6P Docetaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Docetaxel + Sorafenib DCAUVVZ Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Docetaxel + Sorafenib DC68A2R Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Docetaxel + Sorafenib DCTQ5I4 Docetaxel Glioblastoma (Cell Line: SNB-75) [3]
Docetaxel + Sorafenib DC9CC7Z Docetaxel Glioma (Cell Line: SF-539) [3]
Docetaxel + Sorafenib DCRFEZA Docetaxel Glioma (Cell Line: SF-295) [3]
Docetaxel + Sorafenib DCQ323L Docetaxel Glioma (Cell Line: SF-268) [3]
Docetaxel + Sorafenib DCCCCSE Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Docetaxel + Sorafenib DCV7DEI Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Docetaxel + Sorafenib DCNCG98 Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Sorafenib DC98PFW Docetaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Docetaxel + Sorafenib DCKG7TD Docetaxel Malignant melanoma (Cell Line: UACC62) [3]
Docetaxel + Sorafenib DCZA5TY Docetaxel Melanoma (Cell Line: SK-MEL-2) [3]
Docetaxel + Sorafenib DC8S413 Docetaxel Melanoma (Cell Line: UACC-257) [3]
Docetaxel + Sorafenib DCSYSYQ Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Docetaxel + Sorafenib DCZJYXL Docetaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Docetaxel + Sorafenib DCF6PA8 Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Docetaxel + Sorafenib DC717XR Docetaxel Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Docetaxel + Sorafenib DCZEY3J Docetaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Docetaxel + Sorafenib DCEQBV2 Docetaxel Prostate carcinoma (Cell Line: PC-3) [3]
Docetaxel + Sorafenib DCM7R4M Docetaxel Renal cell carcinoma (Cell Line: SN12C) [3]
Docetaxel + Sorafenib DCKVT07 Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Docetaxel + Sorafenib DCB9QEH Docetaxel Carcinoma (Cell Line: RXF 393) [4]
Docetaxel + Sorafenib DCIN5IS Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [4]
Docetaxel + Sorafenib DCCFQ6X Docetaxel Colon carcinoma (Cell Line: KM12) [4]
Docetaxel + Sorafenib DCNOJJD Docetaxel Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Docetaxel + Sorafenib DCTVFRF Docetaxel Invasive ductal carcinoma (Cell Line: BT-549) [4]
Docetaxel + Sorafenib DC6U2KU Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [4]
Doxorubicin + Sorafenib DC4N4XB Doxorubicin Adenocarcinoma (Cell Line: DLD1) [3]
Doxorubicin + Sorafenib DCI1TWJ Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Doxorubicin + Sorafenib DCLY6OR Doxorubicin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Doxorubicin + Sorafenib DCBL077 Doxorubicin Mesothelioma (Cell Line: MSTO) [3]
Doxorubicin + Sorafenib DCR1VEV Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Efavirenz + Sorafenib DCWMCX5 Efavirenz Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Entacapone + Sorafenib DCK5G5O Entacapone Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Epirubicin + Sorafenib DC71BO8 Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Epirubicin + Sorafenib DCTP4FF Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Epirubicin + Sorafenib DCLXMBZ Epirubicin Glioma (Cell Line: SF-539) [3]
Erlotinib + Sorafenib DCHD8E4 Erlotinib Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + Sorafenib DCUVYY3 Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + Sorafenib DCZKXYH Erlotinib Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + Sorafenib DC2CJCA Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [3]
Erlotinib + Sorafenib DCMHKXM Erlotinib Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + Sorafenib DC6BK75 Erlotinib Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + Sorafenib DCF2HRT Erlotinib Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + Sorafenib DC69K63 Erlotinib Adenocarcinoma (Cell Line: HCT116) [3]
Erlotinib + Sorafenib DCLC9MA Erlotinib Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + Sorafenib DCEQFIW Erlotinib Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + Sorafenib DCDMVY5 Erlotinib Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + Sorafenib DCRIXT2 Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + Sorafenib DCFA3OR Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + Sorafenib DC8G4DW Erlotinib Malignant melanoma (Cell Line: A375) [3]
Erlotinib + Sorafenib DCQMTUZ Erlotinib Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + Sorafenib DCOJDYK Erlotinib Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + Sorafenib DCGUZBS Erlotinib Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + Sorafenib DCZG27L Erlotinib Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Sorafenib DCY0TPR Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Sorafenib DCLWIBN Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Sorafenib DCSW0VU Erlotinib Prostate carcinoma (Cell Line: VCAP) [3]
Erlotinib + Sorafenib DCYH4HT Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + Sorafenib DCCHKIG Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + Sorafenib DCLS2SF Erlotinib Breast carcinoma (Cell Line: ZR751) [4]
Erlotinib + Sorafenib DCV24P1 Erlotinib Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + Sorafenib DCEDSMG Erlotinib Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + Sorafenib DC956TS Erlotinib Carcinoma (Cell Line: OV90) [4]
Erlotinib + Sorafenib DCLDEZ1 Erlotinib Carcinoma (Cell Line: MDAMB436) [4]
Erlotinib + Sorafenib DCBLIUB Erlotinib Colon carcinoma (Cell Line: RKO) [4]
Estramustine + Sorafenib DCNNO3T Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Estramustine + Sorafenib DCWW1Y3 Estramustine Breast carcinoma (Cell Line: ZR751) [4]
Estramustine + Sorafenib DCDGI9B Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Estramustine + Sorafenib DC3MSK9 Estramustine Mesothelioma (Cell Line: MSTO) [5]
Ethambutol + Sorafenib DCT0N95 Ethambutol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Etoposide + Sorafenib DCN48PK Etoposide Adenocarcinoma (Cell Line: CAOV3) [3]
Etoposide + Sorafenib DC1HOVO Etoposide Adenocarcinoma (Cell Line: NCIH520) [3]
Etoposide + Sorafenib DCSUHMC Etoposide Adenocarcinoma (Cell Line: COLO320DM) [3]
Etoposide + Sorafenib DCCXLM1 Etoposide Adenocarcinoma (Cell Line: DLD1) [3]
Etoposide + Sorafenib DCPUR7D Etoposide Adenocarcinoma (Cell Line: HCT116) [3]
Etoposide + Sorafenib DCZLJAL Etoposide Adenocarcinoma (Cell Line: SW-620) [3]
Etoposide + Sorafenib DCSZU8N Etoposide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Etoposide + Sorafenib DC54RP4 Etoposide Malignant melanoma (Cell Line: A375) [3]
Etoposide + Sorafenib DCQ1D34 Etoposide Malignant melanoma (Cell Line: HT144) [3]
Etoposide + Sorafenib DCORPO3 Etoposide Malignant melanoma (Cell Line: SKMEL30) [3]
Etoposide + Sorafenib DCI6Q3O Etoposide Mesothelioma (Cell Line: MSTO) [3]
Etoposide + Sorafenib DCV1LMT Etoposide Non small cell carcinoma (Cell Line: SKMES1) [3]
Etoposide + Sorafenib DCU2C8U Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Etoposide + Sorafenib DC9HFU6 Etoposide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Etoposide + Sorafenib DC3KZNM Etoposide Breast carcinoma (Cell Line: ZR751) [4]
Etoposide + Sorafenib DC878Q7 Etoposide Breast carcinoma (Cell Line: KPL1) [4]
Etoposide + Sorafenib DCNMBN0 Etoposide Colon carcinoma (Cell Line: RKO) [4]
Etoposide + Sorafenib DCAR2NP Etoposide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Etoposide + Sorafenib DCEB3Y0 Etoposide Rectal adenocarcinoma (Cell Line: SW837) [4]
Ezetimibe + Sorafenib DCSGSZD Ezetimibe Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Fluorouracil + Sorafenib DC1OA37 Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Fluorouracil + Sorafenib DCFTSG6 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Fluorouracil + Sorafenib DCTQ3GZ Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Fluorouracil + Sorafenib DCIQXOM Fluorouracil Breast carcinoma (Cell Line: ZR751) [4]
Fluorouracil + Sorafenib DC7WUBU Fluorouracil Breast carcinoma (Cell Line: KPL1) [4]
Fluorouracil + Sorafenib DCDC8RI Fluorouracil Breast carcinoma (Cell Line: OCUBM) [4]
Fluorouracil + Sorafenib DCHI12T Fluorouracil Carcinoma (Cell Line: OV90) [4]
Fluorouracil + Sorafenib DCNV46J Fluorouracil Carcinoma (Cell Line: MDAMB436) [4]
Fluorouracil + Sorafenib DC8LUK7 Fluorouracil Colon carcinoma (Cell Line: RKO) [4]
Fluorouracil + Sorafenib DCOZXUJ Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [4]
Fluorouracil + Sorafenib DCLRWZY Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + Sorafenib DCD61BM Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [5]
Fluorouracil + Sorafenib DCJ9YIM Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [5]
Fluorouracil + Sorafenib DC2A9B7 Fluorouracil Adenocarcinoma (Cell Line: A427) [5]
Fluorouracil + Sorafenib DC0942V Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [5]
Fluorouracil + Sorafenib DC0X6ZR Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [5]
Fluorouracil + Sorafenib DCJXFRZ Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [5]
Fluorouracil + Sorafenib DCQNWMG Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [5]
Fluorouracil + Sorafenib DCKPDOA Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [5]
Fluorouracil + Sorafenib DC8L0XO Fluorouracil Adenocarcinoma (Cell Line: DLD1) [5]
Fluorouracil + Sorafenib DC37X0U Fluorouracil Adenocarcinoma (Cell Line: HCT116) [5]
Fluorouracil + Sorafenib DC23U0V Fluorouracil Adenocarcinoma (Cell Line: HT29) [5]
Fluorouracil + Sorafenib DCUCN2J Fluorouracil Adenocarcinoma (Cell Line: SW-620) [5]
Fluorouracil + Sorafenib DC3RDB7 Fluorouracil Amelanotic melanoma (Cell Line: A2058) [5]
Fluorouracil + Sorafenib DCFIV0U Fluorouracil Germ cell tumour (Cell Line: PA1) [5]
Fluorouracil + Sorafenib DCMUSHW Fluorouracil Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Fluorouracil + Sorafenib DCV48SI Fluorouracil Malignant melanoma (Cell Line: A375) [5]
Fluorouracil + Sorafenib DCRG3OY Fluorouracil Malignant melanoma (Cell Line: HT144) [5]
Fluorouracil + Sorafenib DCX3HRI Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [5]
Fluorouracil + Sorafenib DC4R2WU Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [5]
Fluorouracil + Sorafenib DC4FGYG Fluorouracil Malignant melanoma (Cell Line: UACC62) [5]
Fluorouracil + Sorafenib DCM7XB1 Fluorouracil Mesothelioma (Cell Line: MSTO) [5]
Fluorouracil + Sorafenib DCGJ49J Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [5]
Fluorouracil + Sorafenib DC71C2M Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Fluorouracil + Sorafenib DC08FW9 Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Fluorouracil + Sorafenib DCV07OB Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [5]
Fluorouracil + Sorafenib DCEAFZX Fluorouracil Prostate carcinoma (Cell Line: VCAP) [5]
Fulvestrant + Sorafenib DCLEX4Q Fulvestrant Adenocarcinoma (Cell Line: HCT-15) [3]
Fulvestrant + Sorafenib DC067S7 Fulvestrant Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Sorafenib DCSHOXE Fulvestrant Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Fulvestrant + Sorafenib DC7R09K Fulvestrant Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Fulvestrant + Sorafenib DC48XDT Fulvestrant Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Fulvestrant + Sorafenib DCKLE8M Fulvestrant Melanoma (Cell Line: SK-MEL-2) [3]
Galantamine + Sorafenib DCDM0XQ Galantamine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Gefitinib + Sorafenib DC8WPJF Gefitinib Adenocarcinoma (Cell Line: HT29) [3]
Gefitinib + Sorafenib DCS5AU4 Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Gefitinib + Sorafenib DCGQGRK Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [3]
Gefitinib + Sorafenib DCRCPAI Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Gefitinib + Sorafenib DCKF6R2 Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Gefitinib + Sorafenib DC1ITE1 Gefitinib Melanoma (Cell Line: MALME-3M) [3]
Gemcitabine + Sorafenib DCFSTPX Gemcitabine Adenocarcinoma (Cell Line: DLD1) [3]
Gemcitabine + Sorafenib DC3H028 Gemcitabine Amelanotic melanoma (Cell Line: A2058) [3]
Gemcitabine + Sorafenib DCTGYID Gemcitabine Malignant melanoma (Cell Line: HT144) [3]
Gemcitabine + Sorafenib DCQW9KD Gemcitabine Mesothelioma (Cell Line: MSTO) [3]
Gemcitabine + Sorafenib DC3UJFN Gemcitabine Breast carcinoma (Cell Line: ZR751) [4]
GSK525762 + Sorafenib DC5EGYN GSK525762 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
GSK525762 + Sorafenib DCE70HU GSK525762 Breast carcinoma (Cell Line: ZR751) [4]
GSK525762 + Sorafenib DC0EYQ6 GSK525762 Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + Sorafenib DCQ3VOM GSK525762 Breast carcinoma (Cell Line: OCUBM) [4]
GSK525762 + Sorafenib DCQCU28 GSK525762 Carcinoma (Cell Line: MDAMB436) [4]
GSK525762 + Sorafenib DC3ONF7 GSK525762 Colon adenocarcinoma (Cell Line: LOVO) [4]
GSK525762 + Sorafenib DCW9HK2 GSK525762 Colon carcinoma (Cell Line: RKO) [4]
GSK525762 + Sorafenib DCDN4TC GSK525762 Invasive ductal carcinoma (Cell Line: T-47D) [4]
GSK525762 + Sorafenib DCVGBIO GSK525762 Rectal adenocarcinoma (Cell Line: SW837) [4]
GSK525762 + Sorafenib DCF59Q1 GSK525762 Adenocarcinoma (Cell Line: CAOV3) [5]
GSK525762 + Sorafenib DCSKCSD GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [5]
GSK525762 + Sorafenib DCDWYMH GSK525762 Adenocarcinoma (Cell Line: A427) [5]
GSK525762 + Sorafenib DCE71CB GSK525762 Adenocarcinoma (Cell Line: NCIH2122) [5]
GSK525762 + Sorafenib DCAXH7Z GSK525762 Adenocarcinoma (Cell Line: NCIH520) [5]
GSK525762 + Sorafenib DCPQYMC GSK525762 Adenocarcinoma (Cell Line: SW-620) [5]
GSK525762 + Sorafenib DCXV3UM GSK525762 Amelanotic melanoma (Cell Line: A2058) [5]
GSK525762 + Sorafenib DCROL0T GSK525762 Germ cell tumour (Cell Line: PA1) [5]
GSK525762 + Sorafenib DC7MWAL GSK525762 Malignant melanoma (Cell Line: A375) [5]
GSK525762 + Sorafenib DC3QCAO GSK525762 Non small cell carcinoma (Cell Line: SKMES1) [5]
GSK525762 + Sorafenib DC1SWZP GSK525762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Hepzato + Sorafenib DC00MST Hepzato Glioma (Cell Line: SF-268) [3]
Hepzato + Sorafenib DCF9F0K Hepzato Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Hepzato + Sorafenib DCMPI7W Hepzato Adenocarcinoma (Cell Line: DU-145) [5]
Hepzato + Sorafenib DCL25OM Hepzato Adenocarcinoma (Cell Line: NCIH23) [5]
Hepzato + Sorafenib DC1HQ7W Hepzato Adenocarcinoma (Cell Line: HCC-2998) [5]
Hepzato + Sorafenib DCPGWHD Hepzato High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Idarubicin + Sorafenib DCP0UML Idarubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Idarubicin + Sorafenib DCDDDPJ Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Idarubicin + Sorafenib DCBKOJT Idarubicin Breast carcinoma (Cell Line: ZR751) [4]
Idarubicin + Sorafenib DC88A1D Idarubicin Adenocarcinoma (Cell Line: DU-145) [5]
Idarubicin + Sorafenib DCEQ2A0 Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [5]
Idarubicin + Sorafenib DC04R1S Idarubicin Adenocarcinoma (Cell Line: A427) [5]
Idarubicin + Sorafenib DCUS4CO Idarubicin Amelanotic melanoma (Cell Line: A2058) [5]
Idarubicin + Sorafenib DCF3IOF Idarubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Idarubicin + Sorafenib DCW8ZRK Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Idarubicin + Sorafenib DCE72CT Idarubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Idarubicin + Sorafenib DC6F0PY Idarubicin Malignant melanoma (Cell Line: A375) [5]
Idarubicin + Sorafenib DC4I4UN Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Idarubicin + Sorafenib DCSVNF5 Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Imatinib + Sorafenib DCUX9ZY Imatinib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Indazole derivative 5 + Sorafenib DCFPTMO Indazole derivative 5 Adenocarcinoma (Cell Line: HT29) [5]
IT-141 + Sorafenib DCN2W3T IT-141 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Itraconazole + Sorafenib DC800LF Itraconazole Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
JNK-IN-8 + Sorafenib DC6GNLY JNK-IN-8 Astrocytoma (Cell Line: SNB-19) [3]
JNK-IN-8 + Sorafenib DCCS8J8 JNK-IN-8 Glioma (Cell Line: SF-295) [3]
JNK-IN-8 + Sorafenib DCRH3V6 JNK-IN-8 Adenocarcinoma (Cell Line: HCT116) [5]
JNK-IN-8 + Sorafenib DCAEUZ4 JNK-IN-8 Lung adenocarcinoma (Cell Line: HOP-62) [5]
Lapatinib + Sorafenib DC7ALR8 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Lapatinib + Sorafenib DCR4SGU Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Lapatinib + Sorafenib DC9KZXQ Lapatinib Breast carcinoma (Cell Line: ZR751) [4]
Lapatinib + Sorafenib DCA2IP7 Lapatinib Breast carcinoma (Cell Line: KPL1) [4]
Lapatinib + Sorafenib DCUW80A Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
Lapatinib + Sorafenib DCXPOE3 Lapatinib Carcinoma (Cell Line: OV90) [4]
Lapatinib + Sorafenib DCTI7OA Lapatinib Carcinoma (Cell Line: EFM192B) [4]
Lapatinib + Sorafenib DC22NZD Lapatinib Colon carcinoma (Cell Line: RKO) [4]
Lapatinib + Sorafenib DC4S4KY Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Lapatinib + Sorafenib DCG8IDD Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Lapatinib + Sorafenib DC4353L Lapatinib Adenocarcinoma (Cell Line: CAOV3) [5]
Lapatinib + Sorafenib DC3D362 Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Lapatinib + Sorafenib DCKAO7M Lapatinib Adenocarcinoma (Cell Line: A427) [5]
Lapatinib + Sorafenib DCGZYEJ Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [5]
Lapatinib + Sorafenib DC4L6GT Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Lapatinib + Sorafenib DCR5ONT Lapatinib Adenocarcinoma (Cell Line: NCIH520) [5]
Lapatinib + Sorafenib DCE1EM8 Lapatinib Adenocarcinoma (Cell Line: DLD1) [5]
Lapatinib + Sorafenib DCI0SUU Lapatinib Adenocarcinoma (Cell Line: HCT116) [5]
Lapatinib + Sorafenib DCHB97R Lapatinib Adenocarcinoma (Cell Line: SW-620) [5]
Lapatinib + Sorafenib DC9X8P0 Lapatinib Amelanotic melanoma (Cell Line: A2058) [5]
Lapatinib + Sorafenib DC58RBZ Lapatinib Astrocytoma (Cell Line: U251) [5]
Lapatinib + Sorafenib DCY1YKF Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Lapatinib + Sorafenib DCS5JKS Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Lapatinib + Sorafenib DC07ROM Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Lapatinib + Sorafenib DCAULY8 Lapatinib Malignant melanoma (Cell Line: A375) [5]
Lapatinib + Sorafenib DCQGBCJ Lapatinib Malignant melanoma (Cell Line: HT144) [5]
Lapatinib + Sorafenib DC37WZD Lapatinib Malignant melanoma (Cell Line: SKMEL30) [5]
Lapatinib + Sorafenib DCJMOEQ Lapatinib Malignant melanoma (Cell Line: UACC62) [5]
Lapatinib + Sorafenib DC0LPVS Lapatinib Mesothelioma (Cell Line: MSTO) [5]
Lapatinib + Sorafenib DCHOLN4 Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [5]
Lapatinib + Sorafenib DCFLEC7 Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lapatinib + Sorafenib DCMH79C Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Lapatinib + Sorafenib DCU8GEC Lapatinib Prostate carcinoma (Cell Line: LNCAP) [5]
Lapatinib + Sorafenib DCU3US1 Lapatinib Prostate carcinoma (Cell Line: VCAP) [5]
Leflunomide + Sorafenib DCVRH44 Leflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Lenalidomide + Sorafenib DC0MN0J Lenalidomide Adenocarcinoma (Cell Line: DU-145) [5]
Letrozole + Sorafenib DC7HBXR Letrozole Adenocarcinoma (Cell Line: HCT116) [3]
Letrozole + Sorafenib DCUXQ8L Letrozole Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Letrozole + Sorafenib DC7Z1DB Letrozole Lung adenocarcinoma (Cell Line: HOP-62) [3]
Lomustine + Sorafenib DC1WPO8 Lomustine Mesothelioma (Cell Line: MSTO) [5]
Lomustine + Sorafenib DCW9FCW Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lomustine + Sorafenib DC08EY2 Lomustine Prostate carcinoma (Cell Line: LNCAP) [5]
Maprotiline + Sorafenib DCF52ID Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mebutamate + Sorafenib DCTIDE0 Mebutamate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mefloquine + Sorafenib DCF0PRY Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Metformin + Sorafenib DC1G3PU Metformin Adenocarcinoma (Cell Line: OVCAR3) [3]
Metformin + Sorafenib DCC0DKT Metformin Adenocarcinoma (Cell Line: NCIH1650) [3]
Metformin + Sorafenib DCO2CUH Metformin Adenocarcinoma (Cell Line: NCIH520) [3]
Metformin + Sorafenib DCRYCN7 Metformin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Metformin + Sorafenib DCYXW5Q Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Metformin + Sorafenib DCTGDZU Metformin Breast carcinoma (Cell Line: ZR751) [4]
Metformin + Sorafenib DC4KSKC Metformin Breast carcinoma (Cell Line: OCUBM) [4]
Metformin + Sorafenib DCVIC7S Metformin Carcinoma (Cell Line: OV90) [4]
Metformin + Sorafenib DCM7QXP Metformin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Methotrexate + Sorafenib DCE161Q Methotrexate Adenocarcinoma (Cell Line: NCIH23) [3]
Methotrexate + Sorafenib DCCHAT4 Methotrexate Adenocarcinoma (Cell Line: DLD1) [3]
Methotrexate + Sorafenib DCT07KR Methotrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Methotrexate + Sorafenib DC39P7E Methotrexate Carcinoma (Cell Line: EFM192B) [4]
Methotrexate + Sorafenib DCGGCKA Methotrexate Rectal adenocarcinoma (Cell Line: SW837) [4]
Metyrosine + Sorafenib DCKV74S Metyrosine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Mitomycin + Sorafenib DCX0W2S Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Mitomycin + Sorafenib DCVRQQ4 Mitomycin Mesothelioma (Cell Line: MSTO) [5]
MK-1775 + Sorafenib DCL1V7Z MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + Sorafenib DCPDEFK MK-1775 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + Sorafenib DCIP4TF MK-1775 Adenocarcinoma (Cell Line: DLD1) [3]
MK-1775 + Sorafenib DCT8WYP MK-1775 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Sorafenib DCHC4Z3 MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-1775 + Sorafenib DCOBIGC MK-1775 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + Sorafenib DCXA45N MK-1775 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Sorafenib DCME7R0 MK-1775 Malignant melanoma (Cell Line: HT144) [3]
MK-1775 + Sorafenib DC9PTZ7 MK-1775 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Sorafenib DCWRI9F MK-1775 Malignant melanoma (Cell Line: UACC62) [3]
MK-1775 + Sorafenib DCGCMO5 MK-1775 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Sorafenib DC143D3 MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + Sorafenib DCL1G3T MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Sorafenib DCUTN1D MK-1775 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-1775 + Sorafenib DCXTVMS MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-1775 + Sorafenib DCOB8GX MK-1775 Breast carcinoma (Cell Line: ZR751) [4]
MK-1775 + Sorafenib DCUBPCR MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
MK-1775 + Sorafenib DCOHX3C MK-1775 Colon carcinoma (Cell Line: RKO) [4]
MK-1775 + Sorafenib DCK9YXT MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-2206 + Sorafenib DCANQGJ MK-2206 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-2206 + Sorafenib DC3RYYU MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-2206 + Sorafenib DC5KK0G MK-2206 Adenocarcinoma (Cell Line: A427) [3]
MK-2206 + Sorafenib DCL8H0W MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-2206 + Sorafenib DC3N9N0 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-2206 + Sorafenib DCLKY00 MK-2206 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-2206 + Sorafenib DCBI6JQ MK-2206 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-2206 + Sorafenib DC51TOX MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-2206 + Sorafenib DC5P51S MK-2206 Adenocarcinoma (Cell Line: DLD1) [3]
MK-2206 + Sorafenib DCKV3TL MK-2206 Adenocarcinoma (Cell Line: HCT116) [3]
MK-2206 + Sorafenib DCNQZ6J MK-2206 Adenocarcinoma (Cell Line: HT29) [3]
MK-2206 + Sorafenib DCICSLS MK-2206 Adenocarcinoma (Cell Line: SW-620) [3]
MK-2206 + Sorafenib DC89LDE MK-2206 Amelanotic melanoma (Cell Line: A2058) [3]
MK-2206 + Sorafenib DC39DE2 MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-2206 + Sorafenib DCC1TMT MK-2206 Germ cell tumour (Cell Line: PA1) [3]
MK-2206 + Sorafenib DCS58TS MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-2206 + Sorafenib DCA9X0X MK-2206 Malignant melanoma (Cell Line: A375) [3]
MK-2206 + Sorafenib DCL1JZ3 MK-2206 Malignant melanoma (Cell Line: HT144) [3]
MK-2206 + Sorafenib DCQC497 MK-2206 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-2206 + Sorafenib DCAUNBR MK-2206 Malignant melanoma (Cell Line: UACC62) [3]
MK-2206 + Sorafenib DC6DFTK MK-2206 Mesothelioma (Cell Line: MSTO) [3]
MK-2206 + Sorafenib DCJYIES MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-2206 + Sorafenib DCT3YMX MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-2206 + Sorafenib DCNBWJS MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-2206 + Sorafenib DCE4GL3 MK-2206 Prostate carcinoma (Cell Line: VCAP) [3]
MK-2206 + Sorafenib DCQXNV2 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-2206 + Sorafenib DC5A4SM MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-2206 + Sorafenib DCDFPZ4 MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
MK-2206 + Sorafenib DC1GFJR MK-2206 Breast carcinoma (Cell Line: OCUBM) [4]
MK-2206 + Sorafenib DCADJAL MK-2206 Carcinoma (Cell Line: OV90) [4]
MK-2206 + Sorafenib DCL0Z7F MK-2206 Carcinoma (Cell Line: MDAMB436) [4]
MK-2206 + Sorafenib DCISVZJ MK-2206 Colon carcinoma (Cell Line: RKO) [4]
MK-2206 + Sorafenib DC0YYVS MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-2206 + Sorafenib DC8GSHI MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + Sorafenib DCNCD2R MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + Sorafenib DCYM93L MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-4827 + Sorafenib DCPTORE MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + Sorafenib DCV7SVS MK-4827 Breast carcinoma (Cell Line: ZR751) [4]
MK-4827 + Sorafenib DCQZ56N MK-4827 Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + Sorafenib DC9E34I MK-4827 Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + Sorafenib DC9P8WI MK-4827 Carcinoma (Cell Line: OV90) [4]
MK-4827 + Sorafenib DCTXXJY MK-4827 Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + Sorafenib DCHLX3E MK-4827 Carcinoma (Cell Line: MDAMB436) [4]
MK-4827 + Sorafenib DCULKBQ MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-4827 + Sorafenib DCF8BJ9 MK-4827 Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + Sorafenib DC0BHMF MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + Sorafenib DC6CQGY MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + Sorafenib DCKEKRZ MK-4827 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + Sorafenib DCYJPAY MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + Sorafenib DCHVOJ1 MK-4827 Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + Sorafenib DCIJ729 MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-4827 + Sorafenib DC7IGOZ MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + Sorafenib DCOT7Z5 MK-4827 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-4827 + Sorafenib DCKHXU2 MK-4827 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-4827 + Sorafenib DC9T68E MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + Sorafenib DCJXZK1 MK-4827 Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + Sorafenib DC6N11M MK-4827 Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + Sorafenib DC3TKGF MK-4827 Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + Sorafenib DC3MNO2 MK-4827 Adenocarcinoma (Cell Line: SW-620) [5]
MK-4827 + Sorafenib DCAK7EM MK-4827 Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + Sorafenib DCBVNRF MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + Sorafenib DC7U5LQ MK-4827 Malignant melanoma (Cell Line: A375) [5]
MK-4827 + Sorafenib DCMUFUL MK-4827 Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + Sorafenib DCE5Z8I MK-4827 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + Sorafenib DCST48U MK-4827 Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + Sorafenib DCHAPDI MK-4827 Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + Sorafenib DCMHL0J MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + Sorafenib DCO3GCK MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + Sorafenib DCT8R7N MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + Sorafenib DC5HA32 MK-4827 Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + Sorafenib DCR1ZQO MK-4827 Prostate carcinoma (Cell Line: VCAP) [5]
MK-5108 + Sorafenib DCG8VQ0 MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-5108 + Sorafenib DC2V9N0 MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-5108 + Sorafenib DC14Q4A MK-5108 Breast carcinoma (Cell Line: ZR751) [4]
MK-5108 + Sorafenib DCQDCIA MK-5108 Breast carcinoma (Cell Line: KPL1) [4]
MK-5108 + Sorafenib DCLJRRL MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
MK-5108 + Sorafenib DC3WW2U MK-5108 Carcinoma (Cell Line: OV90) [4]
MK-5108 + Sorafenib DCATF7I MK-5108 Carcinoma (Cell Line: EFM192B) [4]
MK-5108 + Sorafenib DCQAJFU MK-5108 Colon carcinoma (Cell Line: RKO) [4]
MK-5108 + Sorafenib DCA7EXK MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-5108 + Sorafenib DC9HKGO MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-5108 + Sorafenib DCXCWT9 MK-5108 Adenocarcinoma (Cell Line: A427) [5]
MK-5108 + Sorafenib DC0AT1A MK-5108 Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-5108 + Sorafenib DCNQV13 MK-5108 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-5108 + Sorafenib DCPWBBG MK-5108 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-5108 + Sorafenib DCHV1WL MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-5108 + Sorafenib DC5QSRV MK-5108 Adenocarcinoma (Cell Line: DLD1) [5]
MK-5108 + Sorafenib DC4SULA MK-5108 Adenocarcinoma (Cell Line: HCT116) [5]
MK-5108 + Sorafenib DCTBZF1 MK-5108 Adenocarcinoma (Cell Line: HT29) [5]
MK-5108 + Sorafenib DCLFUQ3 MK-5108 Adenocarcinoma (Cell Line: SW-620) [5]
MK-5108 + Sorafenib DC6FPGQ MK-5108 Germ cell tumour (Cell Line: PA1) [5]
MK-5108 + Sorafenib DC1FNH0 MK-5108 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-5108 + Sorafenib DCQBBFT MK-5108 Malignant melanoma (Cell Line: A375) [5]
MK-5108 + Sorafenib DCAZK7P MK-5108 Malignant melanoma (Cell Line: HT144) [5]
MK-5108 + Sorafenib DCDP2PY MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-5108 + Sorafenib DCPONNG MK-5108 Malignant melanoma (Cell Line: UACC62) [5]
MK-5108 + Sorafenib DCE6I9H MK-5108 Mesothelioma (Cell Line: MSTO) [5]
MK-5108 + Sorafenib DCFC19C MK-5108 Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-5108 + Sorafenib DCVMSP3 MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-5108 + Sorafenib DCIWCUY MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-5108 + Sorafenib DCUITK2 MK-5108 Prostate carcinoma (Cell Line: VCAP) [5]
Mycophenolic acid + Sorafenib DCRFJ4C Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Nilotinib + Sorafenib DC1R1O1 Nilotinib Clear cell renal cell carcinoma (Cell Line: A498) [3]
Nilotinib + Sorafenib DCA0IG9 Nilotinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Nilotinib + Sorafenib DC2X5H6 Nilotinib Melanoma (Cell Line: SK-MEL-2) [5]
Nilotinib + Sorafenib DCKFVDJ Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
PD-0325901 + Sorafenib DCS22C5 PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Sorafenib DC560M7 PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + Sorafenib DCTKU3C PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + Sorafenib DC50RW8 PD-0325901 Breast carcinoma (Cell Line: ZR751) [4]
PD-0325901 + Sorafenib DC76ANC PD-0325901 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Sorafenib DC3IV0K PD-0325901 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Sorafenib DCTXBBQ PD-0325901 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + Sorafenib DCUD4H1 PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Sorafenib DCXLCWZ PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + Sorafenib DCVU0DP PD-0325901 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + Sorafenib DC596MY PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Sorafenib DCQ3734 PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + Sorafenib DCZYYO1 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [5]
PD-0325901 + Sorafenib DCVUZ8I PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [5]
PD-0325901 + Sorafenib DCKZPM3 PD-0325901 Adenocarcinoma (Cell Line: A427) [5]
PD-0325901 + Sorafenib DCGRZ01 PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [5]
PD-0325901 + Sorafenib DC0EYTD PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [5]
PD-0325901 + Sorafenib DCL93IW PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [5]
PD-0325901 + Sorafenib DCVZZHJ PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [5]
PD-0325901 + Sorafenib DCVME96 PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [5]
PD-0325901 + Sorafenib DCXVS28 PD-0325901 Adenocarcinoma (Cell Line: DLD1) [5]
PD-0325901 + Sorafenib DC982VC PD-0325901 Adenocarcinoma (Cell Line: HCT116) [5]
PD-0325901 + Sorafenib DCN9C8O PD-0325901 Adenocarcinoma (Cell Line: HT29) [5]
PD-0325901 + Sorafenib DCD500B PD-0325901 Adenocarcinoma (Cell Line: SW-620) [5]
PD-0325901 + Sorafenib DCFOM1J PD-0325901 Amelanotic melanoma (Cell Line: A2058) [5]
PD-0325901 + Sorafenib DCSS6RF PD-0325901 Germ cell tumour (Cell Line: PA1) [5]
PD-0325901 + Sorafenib DCM1QFD PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
PD-0325901 + Sorafenib DCQ81MS PD-0325901 Malignant melanoma (Cell Line: A375) [5]
PD-0325901 + Sorafenib DCKN209 PD-0325901 Malignant melanoma (Cell Line: HT144) [5]
PD-0325901 + Sorafenib DC6PXVD PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [5]
PD-0325901 + Sorafenib DCIPK9X PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [5]
PD-0325901 + Sorafenib DC23UHK PD-0325901 Malignant melanoma (Cell Line: UACC62) [5]
PD-0325901 + Sorafenib DC3Q403 PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
PD-0325901 + Sorafenib DC1T7WR PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [5]
PD-0325901 + Sorafenib DCGV0DO PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PD-0325901 + Sorafenib DCSZVM9 PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PD-0325901 + Sorafenib DC1FZ7N PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [5]
PD-0325901 + Sorafenib DC9BP9V PD-0325901 Prostate carcinoma (Cell Line: VCAP) [5]
Pinacidil + Sorafenib DCN7N3R Pinacidil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
PMID28460551-Compound-2 + Sorafenib DCX89NT PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
PMID28460551-Compound-2 + Sorafenib DCJN4WR PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PMID28460551-Compound-2 + Sorafenib DCE5V11 PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PMID28460551-Compound-2 + Sorafenib DC1UXEM PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [4]
PMID28460551-Compound-2 + Sorafenib DC1HG27 PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [4]
PMID28460551-Compound-2 + Sorafenib DCKE4LE PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [4]
PMID28460551-Compound-2 + Sorafenib DCDKOU3 PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [4]
PMID28460551-Compound-2 + Sorafenib DCACYZQ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [5]
PMID28460551-Compound-2 + Sorafenib DCGPFBM PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [5]
PMID28460551-Compound-2 + Sorafenib DC2OJ7D PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [5]
PMID28460551-Compound-2 + Sorafenib DCVS5FW PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [5]
PMID28460551-Compound-2 + Sorafenib DCCHFLA PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [5]
PMID28460551-Compound-2 + Sorafenib DCF8DMH PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [5]
PMID28460551-Compound-2 + Sorafenib DCVHU8M PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
PMID28460551-Compound-2 + Sorafenib DC4ZBKH PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
PMID28460551-Compound-2 + Sorafenib DC911I3 PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [5]
PMID28460551-Compound-2 + Sorafenib DCD0DD2 PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [5]
PMID28460551-Compound-2 + Sorafenib DCENLB1 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
PMID28460551-Compound-2 + Sorafenib DCXV32M PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [5]
PMID28460551-Compound-2 + Sorafenib DCEH3FL PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PMID28460551-Compound-2 + Sorafenib DC3Q20R PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [5]
PMID28460551-Compound-2 + Sorafenib DC87UR8 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [5]
Raloxifene + Sorafenib DC4CICI Raloxifene Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Raloxifene + Sorafenib DC3BX2T Raloxifene Astrocytoma (Cell Line: U251) [3]
Raloxifene + Sorafenib DCVAT3M Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Raloxifene + Sorafenib DC42FA1 Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [3]
Raloxifene + Sorafenib DC0QXXZ Raloxifene Glioma (Cell Line: SF-539) [3]
Raloxifene + Sorafenib DCB590L Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Raloxifene + Sorafenib DCLWKIL Raloxifene Adenocarcinoma (Cell Line: DU-145) [5]
Raloxifene + Sorafenib DC71ZM8 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Raloxifene + Sorafenib DC14E7I Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
RTB101 + Sorafenib DCWSFWI RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
RTB101 + Sorafenib DC5M4WP RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
RTB101 + Sorafenib DCVZWY1 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
RTB101 + Sorafenib DCF2M9K RTB101 Breast carcinoma (Cell Line: OCUBM) [4]
RTB101 + Sorafenib DCOPYPO RTB101 Carcinoma (Cell Line: OV90) [4]
RTB101 + Sorafenib DC4B8MO RTB101 Carcinoma (Cell Line: EFM192B) [4]
RTB101 + Sorafenib DCSDK7Q RTB101 Carcinoma (Cell Line: MDAMB436) [4]
RTB101 + Sorafenib DCC1WXX RTB101 Colon adenocarcinoma (Cell Line: LOVO) [4]
RTB101 + Sorafenib DC0LIV0 RTB101 Colon carcinoma (Cell Line: RKO) [4]
RTB101 + Sorafenib DC8COYX RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [4]
RTB101 + Sorafenib DCWH8ZQ RTB101 Adenocarcinoma (Cell Line: CAOV3) [5]
RTB101 + Sorafenib DC16IMQ RTB101 Adenocarcinoma (Cell Line: A427) [5]
RTB101 + Sorafenib DCAMME7 RTB101 Adenocarcinoma (Cell Line: NCIH23) [5]
RTB101 + Sorafenib DCER6YV RTB101 Adenocarcinoma (Cell Line: NCIH520) [5]
RTB101 + Sorafenib DCBMABY RTB101 Adenocarcinoma (Cell Line: COLO320DM) [5]
RTB101 + Sorafenib DCGOKWW RTB101 Adenocarcinoma (Cell Line: DLD1) [5]
RTB101 + Sorafenib DCY5M0B RTB101 Adenocarcinoma (Cell Line: HT29) [5]
RTB101 + Sorafenib DCV8R3T RTB101 Adenocarcinoma (Cell Line: SW-620) [5]
RTB101 + Sorafenib DCI0JA3 RTB101 Adenocarcinoma (Cell Line: HCT116) [5]
RTB101 + Sorafenib DCD1WE6 RTB101 Amelanotic melanoma (Cell Line: A2058) [5]
RTB101 + Sorafenib DCFDGW8 RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
RTB101 + Sorafenib DCUAEPT RTB101 Malignant melanoma (Cell Line: A375) [5]
RTB101 + Sorafenib DC9E420 RTB101 Malignant melanoma (Cell Line: HT144) [5]
RTB101 + Sorafenib DCBHBJQ RTB101 Malignant melanoma (Cell Line: SKMEL30) [5]
RTB101 + Sorafenib DCH921X RTB101 Malignant melanoma (Cell Line: UACC62) [5]
RTB101 + Sorafenib DC9MEAQ RTB101 Mesothelioma (Cell Line: MSTO) [5]
RTB101 + Sorafenib DCD4HXN RTB101 Non small cell carcinoma (Cell Line: SKMES1) [5]
RTB101 + Sorafenib DCMG216 RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
RTB101 + Sorafenib DCRLTY9 RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
RTB101 + Sorafenib DCELGF6 RTB101 Prostate carcinoma (Cell Line: LNCAP) [5]
RTB101 + Sorafenib DCD077A RTB101 Prostate carcinoma (Cell Line: VCAP) [5]
SCH 727965 + Sorafenib DCZE5D5 SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
SCH 727965 + Sorafenib DCAHTA9 SCH 727965 Breast carcinoma (Cell Line: ZR751) [4]
SCH 727965 + Sorafenib DCPBXNU SCH 727965 Breast carcinoma (Cell Line: OCUBM) [4]
SCH 727965 + Sorafenib DCAZVHM SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SCH 727965 + Sorafenib DCDY5MC SCH 727965 Adenocarcinoma (Cell Line: A427) [5]
SCH 727965 + Sorafenib DC3SELN SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [5]
SCH 727965 + Sorafenib DCQ8OZP SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [5]
SCH 727965 + Sorafenib DCMLQA1 SCH 727965 Adenocarcinoma (Cell Line: DLD1) [5]
SCH 727965 + Sorafenib DCXGQEA SCH 727965 Adenocarcinoma (Cell Line: HCT116) [5]
SCH 727965 + Sorafenib DCT4IYJ SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
SCH 727965 + Sorafenib DCHE3LF SCH 727965 Adenocarcinoma (Cell Line: HCC-2998) [5]
SCH 727965 + Sorafenib DC0O79H SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
SCH 727965 + Sorafenib DCOD5RV SCH 727965 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
SCH 727965 + Sorafenib DCW6IVX SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
SCH 727965 + Sorafenib DCHPOEW SCH 727965 Malignant melanoma (Cell Line: A375) [5]
SCH 727965 + Sorafenib DCZ4VSS SCH 727965 Malignant melanoma (Cell Line: HT144) [5]
SCH 727965 + Sorafenib DCW6K0Q SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [5]
SCH 727965 + Sorafenib DCMSKLL SCH 727965 Malignant melanoma (Cell Line: UACC62) [5]
SCH 727965 + Sorafenib DC1OGA1 SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Silver sulfadiazine + Sorafenib DCTFFUP Silver sulfadiazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sirolimus + Sorafenib DCXR7M3 Sirolimus Glioblastoma (Cell Line: SNB-75) [3]
Sirolimus + Sorafenib DCXIIEC Sirolimus Carcinoma (Cell Line: MCF7) [4]
Sirolimus + Sorafenib DCNC6MS Sirolimus Invasive ductal carcinoma (Cell Line: BT-549) [4]
Sirolimus + Sorafenib DCR8MJA Sirolimus Adenocarcinoma (Cell Line: A549) [5]
Sirolimus + Sorafenib DC1PBBG Sirolimus Melanoma (Cell Line: SK-MEL-2) [5]
Sirolimus + Sorafenib DCBBI5V Sirolimus Melanoma (Cell Line: UACC-257) [5]
Sirolimus + Sorafenib DCBK8YL Sirolimus Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Sirolimus + Sorafenib DCHI6AE Sirolimus Prostate carcinoma (Cell Line: PC-3) [5]
SNX-2112 + Sorafenib DCA96UA SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
SNX-2112 + Sorafenib DCGTG2C SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
SNX-2112 + Sorafenib DC6IMWR SNX-2112 Breast carcinoma (Cell Line: ZR751) [4]
SNX-2112 + Sorafenib DC2RLZU SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
SNX-2112 + Sorafenib DC30C40 SNX-2112 Carcinoma (Cell Line: OV90) [4]
SNX-2112 + Sorafenib DC9YYGB SNX-2112 Colon carcinoma (Cell Line: RKO) [4]
SNX-2112 + Sorafenib DC4164Z SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SNX-2112 + Sorafenib DCVB3UT SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [5]
SNX-2112 + Sorafenib DCBWJZ0 SNX-2112 Adenocarcinoma (Cell Line: A427) [5]
SNX-2112 + Sorafenib DCROH76 SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [5]
SNX-2112 + Sorafenib DCED7WU SNX-2112 Adenocarcinoma (Cell Line: NCIH23) [5]
SNX-2112 + Sorafenib DCS69B1 SNX-2112 Adenocarcinoma (Cell Line: NCIH520) [5]
SNX-2112 + Sorafenib DCT55JS SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [5]
SNX-2112 + Sorafenib DC9A4U8 SNX-2112 Adenocarcinoma (Cell Line: DLD1) [5]
SNX-2112 + Sorafenib DCACM2Y SNX-2112 Adenocarcinoma (Cell Line: HCT116) [5]
SNX-2112 + Sorafenib DC131Y6 SNX-2112 Adenocarcinoma (Cell Line: SW-620) [5]
SNX-2112 + Sorafenib DCD85H8 SNX-2112 Amelanotic melanoma (Cell Line: A2058) [5]
SNX-2112 + Sorafenib DCZF72G SNX-2112 Germ cell tumour (Cell Line: PA1) [5]
SNX-2112 + Sorafenib DCX51A2 SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
SNX-2112 + Sorafenib DC8PFWG SNX-2112 Malignant melanoma (Cell Line: A375) [5]
SNX-2112 + Sorafenib DCGN6SU SNX-2112 Malignant melanoma (Cell Line: HT144) [5]
SNX-2112 + Sorafenib DCLWM6F SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [5]
SNX-2112 + Sorafenib DCU5OT6 SNX-2112 Malignant melanoma (Cell Line: UACC62) [5]
SNX-2112 + Sorafenib DCINNS0 SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
SNX-2112 + Sorafenib DCRU5RJ SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
SNX-2112 + Sorafenib DCDQ8J5 SNX-2112 Prostate carcinoma (Cell Line: VCAP) [5]
Sorafenib + Pentostatin DCE2E52 Pentostatin Adenocarcinoma (Cell Line: HT29) [3]
Sorafenib + Pentostatin DC4LZ9A Pentostatin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Sorafenib + Pentostatin DCTPGIV Pentostatin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Sorafenib + Pentostatin DC157DE Pentostatin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Sorafenib + Pentostatin DCUGY1G Pentostatin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Sorafenib + Pentostatin DCCO1XX Pentostatin Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Pentostatin DCUXLNC Pentostatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Sorafenib + Pentostatin DCS5NYQ Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Sorafenib + Gefitinib DCASRLQ Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Dantrolene DCAQKW5 Dantrolene Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Lumefantrine DC3I0MT Lumefantrine Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Kanamycin DCYRMY6 Kanamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Citalopram DC5BJI2 Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Ixabepilone DCG4VRS Ixabepilone Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Sorafenib + Epinephrine DCYZDIE Epinephrine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + T-3.5 DCOVVS7 T-3.5 DD2 (Cell Line: DD2) [3]
Sorafenib + T-3.5 DCZP6W7 T-3.5 Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Cyclophosphamide DCUA28B Cyclophosphamide Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + Cyclophosphamide DC9BEQ7 Cyclophosphamide Glioma (Cell Line: SF-539) [3]
Sorafenib + Cyclophosphamide DC7CLZH Cyclophosphamide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Sorafenib + Cyclophosphamide DCE8MPN Cyclophosphamide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Sorafenib + Cyclophosphamide DCRS75B Cyclophosphamide Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Sorafenib + Cyclophosphamide DC9VKEC Cyclophosphamide Malignant melanoma (Cell Line: LOX IMVI) [3]
Sorafenib + Cyclophosphamide DCTNH56 Cyclophosphamide Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Cyclophosphamide DCDJNX0 Cyclophosphamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Sorafenib + Panobinostat DCN3DOA Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
Sorafenib + Methotrexate DCP9A5I Methotrexate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Methotrexate DCYUIFX Methotrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Sorafenib + Dihydroergotamine DCHOGHQ Dihydroergotamine DD2 (Cell Line: DD2) [3]
Sorafenib + Miglustat DCL6B9G Miglustat Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Isoniazid DCOV6ET Isoniazid Adenocarcinoma (Cell Line: DU-145) [3]
Sorafenib + Isoniazid DC839OR Isoniazid Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + Isoniazid DCKYYI7 Isoniazid Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Sorafenib + Isoniazid DCTD5KG Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Sorafenib + Isoniazid DCEQJBH Isoniazid Glioma (Cell Line: SF-268) [3]
Sorafenib + Pyrimethamine DC6X059 Pyrimethamine DD2 (Cell Line: DD2) [3]
Sorafenib + Arsenic trioxide DCL6MGI Arsenic trioxide Adenocarcinoma (Cell Line: A549) [3]
Sorafenib + Arsenic trioxide DCQLZR0 Arsenic trioxide Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Sorafenib + Arsenic trioxide DC910AU Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Sorafenib + Arsenic trioxide DCYS81C Arsenic trioxide Malignant melanoma (Cell Line: LOX IMVI) [3]
Sorafenib + SCH-900776 DC81EMZ SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [3]
Sorafenib + SCH-900776 DCBMWF4 SCH-900776 Adenocarcinoma (Cell Line: A427) [3]
Sorafenib + SCH-900776 DCZNKAK SCH-900776 Adenocarcinoma (Cell Line: NCIH1650) [3]
Sorafenib + SCH-900776 DCLK3FG SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [3]
Sorafenib + SCH-900776 DCAW05E SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [3]
Sorafenib + SCH-900776 DCKWV87 SCH-900776 Adenocarcinoma (Cell Line: DLD1) [3]
Sorafenib + SCH-900776 DCRFD5W SCH-900776 Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + SCH-900776 DC38072 SCH-900776 Adenocarcinoma (Cell Line: HT29) [3]
Sorafenib + SCH-900776 DCKIVXQ SCH-900776 Adenocarcinoma (Cell Line: SW-620) [3]
Sorafenib + SCH-900776 DC4S540 SCH-900776 Amelanotic melanoma (Cell Line: A2058) [3]
Sorafenib + SCH-900776 DCQ8Q6M SCH-900776 Germ cell tumour (Cell Line: PA1) [3]
Sorafenib + SCH-900776 DCHJ5YR SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Sorafenib + SCH-900776 DC9W6P1 SCH-900776 Malignant melanoma (Cell Line: A375) [3]
Sorafenib + SCH-900776 DCHNOJL SCH-900776 Malignant melanoma (Cell Line: HT144) [3]
Sorafenib + SCH-900776 DCK7WSQ SCH-900776 Malignant melanoma (Cell Line: UACC62) [3]
Sorafenib + SCH-900776 DC0RPBP SCH-900776 Mesothelioma (Cell Line: MSTO) [3]
Sorafenib + SCH-900776 DCVRF8M SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Sorafenib + SCH-900776 DCIAKHZ SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Sorafenib + SCH-900776 DCEX2RA SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [3]
Sorafenib + SCH-900776 DCO6N32 SCH-900776 Prostate carcinoma (Cell Line: VCAP) [3]
Sorafenib + Plicamycin DCX49U2 Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [3]
Sorafenib + Plicamycin DCV986K Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Sorafenib + Plicamycin DC60YUW Plicamycin Amelanotic melanoma (Cell Line: M14) [3]
Sorafenib + Plicamycin DCTTPOF Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Sorafenib + Plicamycin DCHVR3U Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [3]
Sorafenib + Plicamycin DCKFCN0 Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Sorafenib + Plicamycin DCLUYBJ Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Sorafenib + Plicamycin DCKZ8EG Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Sorafenib + Plicamycin DCQF6W1 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Sorafenib + Plicamycin DCLHQIT Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [3]
Sorafenib + Plicamycin DCJ9B5W Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Sorafenib + Verapamil DCQJL04 Verapamil DD2 (Cell Line: DD2) [3]
Sorafenib + Diltiazem DCTGKDH Diltiazem DD2 (Cell Line: DD2) [3]
Sorafenib + Diltiazem DCGQCQJ Diltiazem Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Pralatrexate DCVSUQX Pralatrexate Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Sorafenib + Pralatrexate DCJWQ3V Pralatrexate Glioblastoma (Cell Line: SNB-75) [3]
Sorafenib + Pralatrexate DCIMXCX Pralatrexate Glioma (Cell Line: SF-295) [3]
Sorafenib + Pralatrexate DC3MMDC Pralatrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Sorafenib + Pralatrexate DCU2BBC Pralatrexate Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Sorafenib + Pralatrexate DCIOR5Z Pralatrexate Prostate carcinoma (Cell Line: PC-3) [3]
Sorafenib + Thiolactomycin DC4D1D1 Thiolactomycin Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Terameprocol DC4XF86 Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [3]
Sorafenib + Terameprocol DC1KTHH Terameprocol Adenocarcinoma (Cell Line: A549) [3]
Sorafenib + Terameprocol DCSB4NZ Terameprocol Adenocarcinoma (Cell Line: NCIH23) [3]
Sorafenib + Terameprocol DCNWDQS Terameprocol Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + Terameprocol DCVFYS1 Terameprocol Adenocarcinoma (Cell Line: HT29) [3]
Sorafenib + Terameprocol DCN6UR2 Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Sorafenib + Terameprocol DCE3M8A Terameprocol Anaplastic large cell lymphoma (Cell Line: SR) [3]
Sorafenib + Terameprocol DC6EQIF Terameprocol Astrocytoma (Cell Line: U251) [3]
Sorafenib + Terameprocol DCKTFWM Terameprocol Astrocytoma (Cell Line: SNB-19) [3]
Sorafenib + Terameprocol DCV41I2 Terameprocol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Sorafenib + Terameprocol DCXG3M2 Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Terameprocol DCW77OV Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [3]
Sorafenib + Terameprocol DCB8D5I Terameprocol Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Sorafenib + Terameprocol DCFG5MD Terameprocol Clear cell renal cell carcinoma (Cell Line: A498) [3]
Sorafenib + Terameprocol DC6X7XF Terameprocol Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Sorafenib + Terameprocol DC3WRMZ Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Sorafenib + Terameprocol DCX4ZVB Terameprocol Glioblastoma (Cell Line: SNB-75) [3]
Sorafenib + Terameprocol DCDJ7CF Terameprocol Glioma (Cell Line: SF-539) [3]
Sorafenib + Terameprocol DCZD0EF Terameprocol Glioma (Cell Line: SF-268) [3]
Sorafenib + Terameprocol DCP2ZIJ Terameprocol Glioma (Cell Line: SF-295) [3]
Sorafenib + Terameprocol DCXBOGY Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Sorafenib + Terameprocol DCTGWDG Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Sorafenib + Terameprocol DCR8OR5 Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Sorafenib + Terameprocol DCIXI1K Terameprocol Lung adenocarcinoma (Cell Line: EKVX) [3]
Sorafenib + Terameprocol DCU8S0N Terameprocol Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Sorafenib + Terameprocol DCIRYWP Terameprocol Lung adenocarcinoma (Cell Line: HOP-62) [3]
Sorafenib + Terameprocol DCQ2WQS Terameprocol Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Sorafenib + Terameprocol DCRU7SD Terameprocol Malignant melanoma (Cell Line: UACC62) [3]
Sorafenib + Terameprocol DCEWZPX Terameprocol Malignant melanoma (Cell Line: LOX IMVI) [3]
Sorafenib + Terameprocol DCNVRVQ Terameprocol Melanoma (Cell Line: MALME-3M) [3]
Sorafenib + Terameprocol DCRL79O Terameprocol Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Terameprocol DCJ61SL Terameprocol Melanoma (Cell Line: SK-MEL-2) [3]
Sorafenib + Terameprocol DC4YX6G Terameprocol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Sorafenib + Terameprocol DCJV308 Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Sorafenib + Terameprocol DCTCJA5 Terameprocol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Sorafenib + Ifosfamide DCQUZ1P Ifosfamide Adenocarcinoma (Cell Line: DU-145) [3]
Sorafenib + Ifosfamide DCW119E Ifosfamide Adenocarcinoma (Cell Line: HT29) [3]
Sorafenib + Ifosfamide DCGAWOL Ifosfamide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Sorafenib + Ifosfamide DC1YYXO Ifosfamide Amelanotic melanoma (Cell Line: M14) [3]
Sorafenib + Ifosfamide DCQHG9I Ifosfamide Astrocytoma (Cell Line: U251) [3]
Sorafenib + Ifosfamide DC54GUG Ifosfamide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Sorafenib + Ifosfamide DCMPMMC Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Sorafenib + Ifosfamide DCRY6KV Ifosfamide Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Sorafenib + Ifosfamide DC2YBAY Ifosfamide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Sorafenib + Ifosfamide DCUWO09 Ifosfamide Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Sorafenib + Ifosfamide DCAU2GZ Ifosfamide Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Sorafenib + Ifosfamide DCS1GO4 Ifosfamide Melanoma (Cell Line: SK-MEL-2) [3]
Sorafenib + Ifosfamide DC4YAVH Ifosfamide Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Ifosfamide DCY7Y44 Ifosfamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Sorafenib + Ifosfamide DCNUSBV Ifosfamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Sorafenib + Ifosfamide DCF0MYT Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Sorafenib + Docetaxel DCRB4S1 Docetaxel DD2 (Cell Line: DD2) [3]
Sorafenib + Phensuximide DC72YME Phensuximide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Fluspirilene DCEW953 Fluspirilene Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + ZM-447439 DC8KSBK ZM-447439 DD2 (Cell Line: DD2) [3]
Sorafenib + Sarpogrelate DCOOENN Sarpogrelate DD2 (Cell Line: DD2) [3]
Sorafenib + Sarpogrelate DC3ZELQ Sarpogrelate Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Mitomycin DCQ8RK3 Mitomycin Adenocarcinoma (Cell Line: DU-145) [3]
Sorafenib + Mitomycin DCSIX1F Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Sorafenib + Mitomycin DCRETGN Mitomycin Lung adenocarcinoma (Cell Line: EKVX) [3]
Sorafenib + Mitomycin DCPT2GS Mitomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Sorafenib + Mitomycin DCSIZTH Mitomycin Prostate carcinoma (Cell Line: PC-3) [3]
Sorafenib + Ivermectin DCSWNWO Ivermectin DD2 (Cell Line: DD2) [3]
Sorafenib + Procarbazine DCC1WC7 Procarbazine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + BIO-300 DCCP6Q0 BIO-300 Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + SB 228357 DCE2MLJ SB 228357 Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Altretamine DC1ZLS5 Altretamine Adenocarcinoma (Cell Line: DU-145) [3]
Sorafenib + Altretamine DCQNSWG Altretamine Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + Altretamine DCLLKDX Altretamine Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Sorafenib + Altretamine DCC493Q Altretamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Sorafenib + Altretamine DCT7AO5 Altretamine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Sorafenib + Altretamine DC2LD79 Altretamine Lung adenocarcinoma (Cell Line: EKVX) [3]
Sorafenib + Altretamine DCT3BX2 Altretamine Melanoma (Cell Line: MALME-3M) [3]
Sorafenib + Diazoxide DCEYVGI Diazoxide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Ridaforolimus DCRZFHB Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [3]
Sorafenib + Ridaforolimus DCUSMD8 Ridaforolimus Adenocarcinoma (Cell Line: A427) [3]
Sorafenib + Ridaforolimus DCTC7VP Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [3]
Sorafenib + Ridaforolimus DCG5WD0 Ridaforolimus Adenocarcinoma (Cell Line: SW-620) [3]
Sorafenib + Ridaforolimus DCPVBPO Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [3]
Sorafenib + Ridaforolimus DCBLHZW Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Sorafenib + Ridaforolimus DC9GBXS Ridaforolimus Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Sorafenib + Ridaforolimus DCBS4D2 Ridaforolimus Malignant melanoma (Cell Line: A375) [3]
Sorafenib + Ridaforolimus DC78PJK Ridaforolimus Malignant melanoma (Cell Line: HT144) [3]
Sorafenib + Ridaforolimus DCP6H8I Ridaforolimus Malignant melanoma (Cell Line: SKMEL30) [3]
Sorafenib + Ridaforolimus DCSBPF8 Ridaforolimus Malignant melanoma (Cell Line: UACC62) [3]
Sorafenib + Ridaforolimus DCOW676 Ridaforolimus Mesothelioma (Cell Line: MSTO) [3]
Sorafenib + Ridaforolimus DCS3ZW4 Ridaforolimus Non small cell carcinoma (Cell Line: SKMES1) [3]
Sorafenib + Ridaforolimus DCB1JHR Ridaforolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Sorafenib + TEM DC82QZF TEM Adenocarcinoma (Cell Line: NCIH23) [3]
Sorafenib + TEM DCZ78P3 TEM Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Sorafenib + Idarubicin DCYWNXI Idarubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Idarubicin DC7YWQF Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Sorafenib + Bortezomib DCNGUZO Bortezomib Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Miconazole DC2EZUS Miconazole DD2 (Cell Line: DD2) [3]
Sorafenib + Omacetaxine mepesuccinate DCTK2LJ Omacetaxine mepesuccinate DD2 (Cell Line: DD2) [3]
Sorafenib + Omacetaxine mepesuccinate DCVYS9Q Omacetaxine mepesuccinate Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Chlorambucil DCP7QF6 Chlorambucil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Chlorambucil DCIHDZV Chlorambucil Clear cell renal cell carcinoma (Cell Line: A498) [3]
Sorafenib + Chlorambucil DCFX6AO Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [3]
Sorafenib + Brincidofovir DCY8IWL Brincidofovir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + ER819762 DCQGG2W ER819762 Adenocarcinoma (Cell Line: HT29) [3]
Sorafenib + ER819762 DCTN08E ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Sorafenib + ER819762 DCYJ8RM ER819762 Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Sorafenib + ER819762 DC97YW9 ER819762 Glioma (Cell Line: SF-295) [3]
Sorafenib + ER819762 DCEX2CV ER819762 Lung adenocarcinoma (Cell Line: HOP-62) [3]
Sorafenib + ER819762 DCB3ZOS ER819762 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Sorafenib + Pomalidomide DCC488L Pomalidomide Adenocarcinoma (Cell Line: A549) [3]
Sorafenib + Pomalidomide DCKC03S Pomalidomide Adenocarcinoma (Cell Line: HT29) [3]
Sorafenib + Pomalidomide DCAQ3ZT Pomalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Sorafenib + Pomalidomide DC11K7N Pomalidomide Amelanotic melanoma (Cell Line: M14) [3]
Sorafenib + Pomalidomide DC60TDJ Pomalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Sorafenib + Pomalidomide DCF2CZ8 Pomalidomide Glioblastoma (Cell Line: SNB-75) [3]
Sorafenib + Pomalidomide DC8NNXY Pomalidomide Lung adenocarcinoma (Cell Line: EKVX) [3]
Sorafenib + Pomalidomide DCUB5Z4 Pomalidomide Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Sorafenib + Pomalidomide DCZILKF Pomalidomide Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Vinflunine DCOLMT8 Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Sorafenib + Vinflunine DCRAW0Y Vinflunine Clear cell renal cell carcinoma (Cell Line: A498) [3]
Sorafenib + Vinflunine DC4URY3 Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Sorafenib + Vinflunine DC5N3ZZ Vinflunine Glioma (Cell Line: SF-539) [3]
Sorafenib + Vinflunine DC33W85 Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Sorafenib + Vinflunine DCQB30S Vinflunine Malignant melanoma (Cell Line: UACC62) [3]
Sorafenib + Vinflunine DCYC8QO Vinflunine Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Vinflunine DCDA4D4 Vinflunine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Sorafenib + Mycophenolic acid DC8FH0K Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Bifemelane DC3OSQR Bifemelane DD2 (Cell Line: DD2) [3]
Sorafenib + Ritonavir DCH0OM5 Ritonavir Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Mepacrine DCEX5VI Mepacrine Adenocarcinoma (Cell Line: OVCAR3) [3]
Sorafenib + Mepacrine DCM7YVZ Mepacrine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Sorafenib + Mepacrine DCCPH48 Mepacrine Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Sorafenib + Pyronaridine DC3JRV6 Pyronaridine DD2 (Cell Line: DD2) [3]
Sorafenib + Mefloquine DCU9GQS Mefloquine DD2 (Cell Line: DD2) [3]
Sorafenib + Mefloquine DCXVF3T Mefloquine Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Olmesartan medoxomil DC8SBN1 Olmesartan medoxomil Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + PMID28870136-Compound-43 DC8QJHU PMID28870136-Compound-43 Adenocarcinoma (Cell Line: NCIH23) [3]
Sorafenib + PMID28870136-Compound-43 DCGJ345 PMID28870136-Compound-43 Astrocytoma (Cell Line: U251) [3]
Sorafenib + PMID28870136-Compound-43 DCTJYGY PMID28870136-Compound-43 Glioma (Cell Line: SF-295) [3]
Sorafenib + PMID28870136-Compound-43 DCKMH8S PMID28870136-Compound-43 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Sorafenib + PMID28870136-Compound-43 DCUOVPS PMID28870136-Compound-43 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Sorafenib + PMID28870136-Compound-43 DCRVOCK PMID28870136-Compound-43 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Sorafenib + PMID28870136-Compound-43 DCPZNGM PMID28870136-Compound-43 Renal cell carcinoma (Cell Line: SN12C) [3]
Sorafenib + FORMESTANE DCTGXWT FORMESTANE Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Sorafenib + FORMESTANE DCZVTT8 FORMESTANE Renal cell carcinoma (Cell Line: UO-31) [3]
Sorafenib + Vorinostat DC22E23 Vorinostat Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Aminolevulinic Acid Hydrochloride DCQ8SUW Aminolevulinic Acid Hydrochloride Astrocytoma (Cell Line: U251) [3]
Sorafenib + Aminolevulinic Acid Hydrochloride DCL1VUT Aminolevulinic Acid Hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Sorafenib + Aminolevulinic Acid Hydrochloride DC0EA7F Aminolevulinic Acid Hydrochloride Malignant melanoma (Cell Line: LOX IMVI) [3]
Sorafenib + Aminolevulinic Acid Hydrochloride DCJZL7O Aminolevulinic Acid Hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Sorafenib + Aminolevulinic Acid Hydrochloride DCLNZWG Aminolevulinic Acid Hydrochloride Renal cell carcinoma (Cell Line: SN12C) [3]
Sorafenib + Atovaquone DCEI834 Atovaquone Hepatoblastoma (Cell Line: HB3) [3]
Sorafenib + Aciclovir DCTXLMT Aciclovir Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Cytarabine DCAWCKJ Cytarabine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Sorafenib + Pentostatin DCU3A13 Pentostatin Colon carcinoma (Cell Line: KM12) [4]
Sorafenib + Ixabepilone DCYC52A Ixabepilone Carcinoma (Cell Line: MCF7) [4]
Sorafenib + Ixabepilone DCECKT2 Ixabepilone Colon adenocarcinoma (Cell Line: COLO 205) [4]
Sorafenib + Ixabepilone DC94IV1 Ixabepilone Colon carcinoma (Cell Line: KM12) [4]
Sorafenib + Ixabepilone DC4I4PL Ixabepilone Invasive ductal carcinoma (Cell Line: T-47D) [4]
Sorafenib + SCH-900776 DCZ568W SCH-900776 Breast carcinoma (Cell Line: ZR751) [4]
Sorafenib + SCH-900776 DCI85JI SCH-900776 Breast carcinoma (Cell Line: OCUBM) [4]
Sorafenib + SCH-900776 DCMAZTI SCH-900776 Carcinoma (Cell Line: OV90) [4]
Sorafenib + SCH-900776 DC5PK6D SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Sorafenib + Plicamycin DCP2I4Z Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Sorafenib + Plicamycin DCGPLRG Plicamycin Colon carcinoma (Cell Line: KM12) [4]
Sorafenib + Terameprocol DCXZ74U Terameprocol Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Sorafenib + Terameprocol DC59M98 Terameprocol Colon carcinoma (Cell Line: KM12) [4]
Sorafenib + Terameprocol DCPWVIL Terameprocol Invasive ductal carcinoma (Cell Line: T-47D) [4]
Sorafenib + Terameprocol DC67Q5H Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Sorafenib + Terameprocol DCK8ZC0 Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [4]
Sorafenib + Ifosfamide DCUI0XG Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Sorafenib + Mitomycin DCW6RIO Mitomycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Sorafenib + Altretamine DCR4YCQ Altretamine Carcinoma (Cell Line: RXF 393) [4]
Sorafenib + Altretamine DCEO53Q Altretamine Colon carcinoma (Cell Line: KM12) [4]
Sorafenib + Ridaforolimus DC1NRHB Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Sorafenib + Ridaforolimus DCRP8UX Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [4]
Sorafenib + Ridaforolimus DCQR502 Ridaforolimus Carcinoma (Cell Line: OV90) [4]
Sorafenib + Ridaforolimus DC45XJ5 Ridaforolimus Colon carcinoma (Cell Line: RKO) [4]
Sorafenib + Ridaforolimus DC371OS Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
Sorafenib + TEM DCSJ9RU TEM Carcinoma (Cell Line: RXF 393) [4]
Sorafenib + ER819762 DCYWLLK ER819762 Carcinoma (Cell Line: RXF 393) [4]
Sorafenib + ER819762 DCSKKAY ER819762 Carcinoma (Cell Line: MCF7) [4]
Sorafenib + ER819762 DCD5D0T ER819762 Colon carcinoma (Cell Line: KM12) [4]
Sorafenib + Pomalidomide DC47SGR Pomalidomide Carcinoma (Cell Line: RXF 393) [4]
Sorafenib + Vinflunine DCN1JC4 Vinflunine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Sorafenib + Aminolevulinic Acid Hydrochloride DCYKREL Aminolevulinic Acid Hydrochloride Invasive ductal carcinoma (Cell Line: T-47D) [4]
SY-1425 + Sorafenib DCDIHX5 SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
SY-1425 + Sorafenib DCNEIOK SY-1425 Astrocytoma (Cell Line: U251) [3]
SY-1425 + Sorafenib DCYS24P SY-1425 Astrocytoma (Cell Line: SNB-19) [3]
SY-1425 + Sorafenib DC8OJG7 SY-1425 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
SY-1425 + Sorafenib DCWU39R SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [3]
SY-1425 + Sorafenib DCXTLIK SY-1425 Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
SY-1425 + Sorafenib DCBTQSW SY-1425 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
SY-1425 + Sorafenib DCIIU4G SY-1425 Clear cell renal cell carcinoma (Cell Line: A498) [3]
SY-1425 + Sorafenib DCZWBTS SY-1425 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
SY-1425 + Sorafenib DCNTFMT SY-1425 Glioma (Cell Line: SF-295) [3]
SY-1425 + Sorafenib DCVYY74 SY-1425 Glioma (Cell Line: SF-268) [3]
SY-1425 + Sorafenib DCSWX52 SY-1425 Papillary renal cell carcinoma (Cell Line: ACHN) [3]
SY-1425 + Sorafenib DC5K1UA SY-1425 Renal cell carcinoma (Cell Line: UO-31) [3]
SY-1425 + Sorafenib DCDRAJT SY-1425 Carcinoma (Cell Line: RXF 393) [4]
SY-1425 + Sorafenib DCT06GQ SY-1425 Colon adenocarcinoma (Cell Line: COLO 205) [4]
SY-1425 + Sorafenib DC8LVNY SY-1425 Colon carcinoma (Cell Line: KM12) [4]
SY-1425 + Sorafenib DCKHLWP SY-1425 Invasive ductal carcinoma (Cell Line: BT-549) [4]
SY-1425 + Sorafenib DCFQI14 SY-1425 Adenocarcinoma (Cell Line: DU-145) [5]
SY-1425 + Sorafenib DCQ879E SY-1425 Adenocarcinoma (Cell Line: OVCAR3) [5]
SY-1425 + Sorafenib DCNXRGP SY-1425 Adenocarcinoma (Cell Line: NCIH23) [5]
SY-1425 + Sorafenib DCUT485 SY-1425 Adenocarcinoma (Cell Line: HT29) [5]
SY-1425 + Sorafenib DCJ3MW0 SY-1425 Adenocarcinoma (Cell Line: HCT-15) [5]
SY-1425 + Sorafenib DCOAYAL SY-1425 Adenocarcinoma (Cell Line: HCC-2998) [5]
SY-1425 + Sorafenib DCPY8OD SY-1425 Amelanotic melanoma (Cell Line: M14) [5]
SY-1425 + Sorafenib DCDB5Z9 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
SY-1425 + Sorafenib DCQR7BS SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
SY-1425 + Sorafenib DC7PDZ1 SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
SY-1425 + Sorafenib DCDZB03 SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
SY-1425 + Sorafenib DCZNQ9H SY-1425 Lung adenocarcinoma (Cell Line: HOP-62) [5]
SY-1425 + Sorafenib DCQT1RP SY-1425 Lung adenocarcinoma (Cell Line: EKVX) [5]
SY-1425 + Sorafenib DCTGDMW SY-1425 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
SY-1425 + Sorafenib DCMQMV2 SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
SY-1425 + Sorafenib DC2YUPY SY-1425 Malignant melanoma (Cell Line: UACC62) [5]
SY-1425 + Sorafenib DCID5RW SY-1425 Malignant melanoma (Cell Line: LOX IMVI) [5]
SY-1425 + Sorafenib DC2GSRR SY-1425 Melanoma (Cell Line: UACC-257) [5]
SY-1425 + Sorafenib DCNJIUK SY-1425 Melanoma (Cell Line: SK-MEL-2) [5]
SY-1425 + Sorafenib DCIWW5M SY-1425 Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
SY-1425 + Sorafenib DCF7PLC SY-1425 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
SY-1425 + Sorafenib DCH20XY SY-1425 Prostate carcinoma (Cell Line: PC-3) [5]
Taxol + Sorafenib DC9T1GO Taxol Anaplastic large cell lymphoma (Cell Line: SR) [3]
Taxol + Sorafenib DCH8VPM Taxol Astrocytoma (Cell Line: SNB-19) [3]
Taxol + Sorafenib DCE5I64 Taxol Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Taxol + Sorafenib DCIGAFZ Taxol Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Taxol + Sorafenib DC53KDW Taxol Clear cell renal cell carcinoma (Cell Line: A498) [3]
Taxol + Sorafenib DCEIQCH Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Taxol + Sorafenib DCPZ4TH Taxol Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Taxol + Sorafenib DC37TC3 Taxol Breast carcinoma (Cell Line: ZR751) [4]
Taxol + Sorafenib DCHILCM Taxol Carcinoma (Cell Line: OV90) [4]
Taxol + Sorafenib DCQMHOP Taxol Carcinoma (Cell Line: RXF 393) [4]
Taxol + Sorafenib DCPF3VB Taxol Carcinoma (Cell Line: MCF7) [4]
Taxol + Sorafenib DCXZ0S6 Taxol Colon carcinoma (Cell Line: RKO) [4]
Taxol + Sorafenib DCL5P58 Taxol Colon carcinoma (Cell Line: KM12) [4]
Taxol + Sorafenib DC3JA3H Taxol Invasive ductal carcinoma (Cell Line: T-47D) [4]
Taxol + Sorafenib DC69G57 Taxol Invasive ductal carcinoma (Cell Line: BT-549) [4]
Taxol + Sorafenib DCW62WB Taxol Adenocarcinoma (Cell Line: DU-145) [5]
Taxol + Sorafenib DCF6TGX Taxol Adenocarcinoma (Cell Line: CAOV3) [5]
Taxol + Sorafenib DCBMSK6 Taxol Adenocarcinoma (Cell Line: A427) [5]
Taxol + Sorafenib DCV67M5 Taxol Adenocarcinoma (Cell Line: NCIH520) [5]
Taxol + Sorafenib DCSF9CV Taxol Adenocarcinoma (Cell Line: NCIH23) [5]
Taxol + Sorafenib DC6LD27 Taxol Adenocarcinoma (Cell Line: A549) [5]
Taxol + Sorafenib DCKQO5S Taxol Adenocarcinoma (Cell Line: COLO320DM) [5]
Taxol + Sorafenib DCE90P1 Taxol Adenocarcinoma (Cell Line: DLD1) [5]
Taxol + Sorafenib DCBBQ0R Taxol Adenocarcinoma (Cell Line: SW-620) [5]
Taxol + Sorafenib DCCEK7D Taxol Adenocarcinoma (Cell Line: HCC-2998) [5]
Taxol + Sorafenib DCO2XCW Taxol Adenocarcinoma (Cell Line: HCT116) [5]
Taxol + Sorafenib DCG1YVV Taxol Amelanotic melanoma (Cell Line: M14) [5]
Taxol + Sorafenib DC5CII6 Taxol Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Taxol + Sorafenib DCGQDLR Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Taxol + Sorafenib DC5X10G Taxol Lung adenocarcinoma (Cell Line: HOP-62) [5]
Taxol + Sorafenib DCQGULY Taxol Malignant melanoma (Cell Line: A375) [5]
Taxol + Sorafenib DCQANO2 Taxol Malignant melanoma (Cell Line: HT144) [5]
Taxol + Sorafenib DCWRKYG Taxol Malignant melanoma (Cell Line: LOX IMVI) [5]
Taxol + Sorafenib DC86565 Taxol Melanoma (Cell Line: SK-MEL-2) [5]
Taxol + Sorafenib DC0ON9S Taxol Melanoma (Cell Line: UACC-257) [5]
Taxol + Sorafenib DCJDXEG Taxol Mesothelioma (Cell Line: MSTO) [5]
Taxol + Sorafenib DCF3S7C Taxol Non small cell carcinoma (Cell Line: SKMES1) [5]
Taxol + Sorafenib DC2Z9B1 Taxol Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Taxol + Sorafenib DC4YN4B Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Taxol + Sorafenib DCTD4BC Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Taxol + Sorafenib DC6VYQG Taxol Prostate carcinoma (Cell Line: VCAP) [5]
Taxol + Sorafenib DC0O4S5 Taxol Prostate carcinoma (Cell Line: PC-3) [5]
Testosterone cypionate + Sorafenib DC4RO6F Testosterone cypionate Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Thioguanine + Sorafenib DC0U696 Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Thioguanine + Sorafenib DCMEW3I Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Thioguanine + Sorafenib DCHIX5J Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Thioguanine + Sorafenib DCU93HQ Thioguanine Astrocytoma (Cell Line: SNB-19) [3]
Thioguanine + Sorafenib DCNZXDY Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Thioguanine + Sorafenib DCSYMXC Thioguanine Glioma (Cell Line: SF-295) [3]
Thioguanine + Sorafenib DCIHRHJ Thioguanine Adenocarcinoma (Cell Line: DU-145) [5]
Thioguanine + Sorafenib DCLEJOQ Thioguanine Malignant melanoma (Cell Line: UACC62) [5]
Tiagabine + Sorafenib DCSDMS9 Tiagabine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Topotecan + Sorafenib DCFYBVP Topotecan Breast carcinoma (Cell Line: ZR751) [4]
Topotecan + Sorafenib DC14B5H Topotecan Invasive ductal carcinoma (Cell Line: T-47D) [4]
Topotecan + Sorafenib DCVBGAT Topotecan Adenocarcinoma (Cell Line: A427) [5]
Topotecan + Sorafenib DC0OWBE Topotecan Adenocarcinoma (Cell Line: NCIH520) [5]
Topotecan + Sorafenib DCYNBW8 Topotecan Adenocarcinoma (Cell Line: A549) [5]
Topotecan + Sorafenib DCSMTZS Topotecan Adenocarcinoma (Cell Line: DLD1) [5]
Topotecan + Sorafenib DCA7TT1 Topotecan Adenocarcinoma (Cell Line: HT29) [5]
Topotecan + Sorafenib DCS3NH5 Topotecan Adenocarcinoma (Cell Line: SW-620) [5]
Topotecan + Sorafenib DC2T98X Topotecan Amelanotic melanoma (Cell Line: A2058) [5]
Topotecan + Sorafenib DCAWWMX Topotecan Astrocytoma (Cell Line: SNB-19) [5]
Topotecan + Sorafenib DCSBLHZ Topotecan Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Topotecan + Sorafenib DCQHUVS Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Topotecan + Sorafenib DCBQ211 Topotecan Germ cell tumour (Cell Line: PA1) [5]
Topotecan + Sorafenib DCBUT1Q Topotecan Malignant melanoma (Cell Line: HT144) [5]
Topotecan + Sorafenib DC0B1GW Topotecan Malignant melanoma (Cell Line: SKMEL30) [5]
Topotecan + Sorafenib DC058K8 Topotecan Melanoma (Cell Line: MALME-3M) [5]
Topotecan + Sorafenib DC3K6EY Topotecan Mesothelioma (Cell Line: MSTO) [5]
Topotecan + Sorafenib DC19EV7 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Topotecan + Sorafenib DCV4MVM Topotecan Non small cell carcinoma (Cell Line: SKMES1) [5]
Topotecan + Sorafenib DC8G29P Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Topotecan + Sorafenib DCMFU3T Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + Sorafenib DCWY8KH Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Topotecan + Sorafenib DCX5QKC Topotecan Prostate carcinoma (Cell Line: VCAP) [5]
Triapine + Sorafenib DCUEXNP Triapine Adenocarcinoma (Cell Line: HCT-15) [5]
Triapine + Sorafenib DCQS1NS Triapine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Triapine + Sorafenib DC4MK8Y Triapine Malignant melanoma (Cell Line: LOX IMVI) [5]
Trifluridine + Sorafenib DC7BWXB Trifluridine Astrocytoma (Cell Line: SNB-19) [3]
Trifluridine + Sorafenib DCBC0SW Trifluridine Adenocarcinoma (Cell Line: DU-145) [5]
Trifluridine + Sorafenib DCSELCY Trifluridine Adenocarcinoma (Cell Line: NCIH23) [5]
Trifluridine + Sorafenib DCNTPHG Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Trifluridine + Sorafenib DCHTTTK Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Trifluridine + Sorafenib DCK1CRX Trifluridine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Trimethobenzamide + Sorafenib DCPG5RU Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Trioxsalen + Sorafenib DCWX3FK Trioxsalen Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Uracil mustard + Sorafenib DCMW6YH Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Uracil mustard + Sorafenib DCNMTF5 Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Uracil mustard + Sorafenib DCTOVCX Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [3]
Uracil mustard + Sorafenib DCFBDNO Uracil mustard Astrocytoma (Cell Line: SNB-19) [3]
Uracil mustard + Sorafenib DCW1Y1K Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Uracil mustard + Sorafenib DC0K17X Uracil mustard Glioma (Cell Line: SF-295) [3]
Uracil mustard + Sorafenib DCTEA79 Uracil mustard Adenocarcinoma (Cell Line: DU-145) [5]
Uracil mustard + Sorafenib DCBTE3Q Uracil mustard Adenocarcinoma (Cell Line: NCIH23) [5]
Uracil mustard + Sorafenib DCP7Y8S Uracil mustard Adenocarcinoma (Cell Line: A549) [5]
Uracil mustard + Sorafenib DCKY54S Uracil mustard Adenocarcinoma (Cell Line: HT29) [5]
Uracil mustard + Sorafenib DCJO529 Uracil mustard Adenocarcinoma (Cell Line: HCT116) [5]
Vandetanib + Sorafenib DCT4X3M Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vemurafenib + Sorafenib DCOKFP0 Vemurafenib Melanoma (Cell Line: UACC-257) [5]
Vinblastine + Sorafenib DCQJ6UE Vinblastine Adenocarcinoma (Cell Line: CAOV3) [3]
Vinblastine + Sorafenib DC3N6DP Vinblastine Adenocarcinoma (Cell Line: A427) [3]
Vinblastine + Sorafenib DCDS8AV Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [3]
Vinblastine + Sorafenib DC7P7DY Vinblastine Adenocarcinoma (Cell Line: NCIH23) [3]
Vinblastine + Sorafenib DC023Z8 Vinblastine Adenocarcinoma (Cell Line: NCIH520) [3]
Vinblastine + Sorafenib DCVE6UB Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [3]
Vinblastine + Sorafenib DCDAOTZ Vinblastine Adenocarcinoma (Cell Line: DLD1) [3]
Vinblastine + Sorafenib DCXEWDG Vinblastine Adenocarcinoma (Cell Line: HCT116) [3]
Vinblastine + Sorafenib DCH033B Vinblastine Adenocarcinoma (Cell Line: SW-620) [3]
Vinblastine + Sorafenib DCXX7ZN Vinblastine Amelanotic melanoma (Cell Line: A2058) [3]
Vinblastine + Sorafenib DCKKPBC Vinblastine Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Vinblastine + Sorafenib DCL5AVV Vinblastine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Vinblastine + Sorafenib DCFMFIN Vinblastine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vinblastine + Sorafenib DCZMEC9 Vinblastine Malignant melanoma (Cell Line: A375) [3]
Vinblastine + Sorafenib DCBTUV6 Vinblastine Malignant melanoma (Cell Line: HT144) [3]
Vinblastine + Sorafenib DCNWFPX Vinblastine Malignant melanoma (Cell Line: SKMEL30) [3]
Vinblastine + Sorafenib DCGW0W9 Vinblastine Malignant melanoma (Cell Line: UACC62) [3]
Vinblastine + Sorafenib DCUIOGM Vinblastine Mesothelioma (Cell Line: MSTO) [3]
Vinblastine + Sorafenib DC1IS6S Vinblastine Non small cell carcinoma (Cell Line: SKMES1) [3]
Vinblastine + Sorafenib DCS903P Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Vinblastine + Sorafenib DCI2VFY Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Vinblastine + Sorafenib DCJ9AN9 Vinblastine Prostate carcinoma (Cell Line: LNCAP) [3]
Vinblastine + Sorafenib DCLWKZ0 Vinblastine Prostate carcinoma (Cell Line: VCAP) [3]
Vinblastine + Sorafenib DC21CRB Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinblastine + Sorafenib DCA3BEA Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinblastine + Sorafenib DCCGGN5 Vinblastine Breast carcinoma (Cell Line: ZR751) [4]
Vinblastine + Sorafenib DC4DGIL Vinblastine Breast carcinoma (Cell Line: KPL1) [4]
Vinblastine + Sorafenib DCKBARM Vinblastine Breast carcinoma (Cell Line: OCUBM) [4]
Vinblastine + Sorafenib DCKWEQ2 Vinblastine Carcinoma (Cell Line: OV90) [4]
Vinblastine + Sorafenib DCCQ5LR Vinblastine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinblastine + Sorafenib DC2KHHW Vinblastine Colon carcinoma (Cell Line: RKO) [4]
Vinblastine + Sorafenib DC1MS1D Vinblastine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinblastine + Sorafenib DCD7AVE Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vincristine + Sorafenib DCBRIBM Vincristine Adenocarcinoma (Cell Line: DU-145) [3]
Vincristine + Sorafenib DC144DL Vincristine Adenocarcinoma (Cell Line: HT29) [3]
Vincristine + Sorafenib DCES7ZH Vincristine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Vincristine + Sorafenib DC9IFTA Vincristine Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Vinorelbine + Sorafenib DCX7HTN Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + Sorafenib DCWTFXV Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + Sorafenib DCTEA6G Vinorelbine Breast carcinoma (Cell Line: ZR751) [4]
Vinorelbine + Sorafenib DCE4GMO Vinorelbine Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + Sorafenib DCP4D30 Vinorelbine Carcinoma (Cell Line: OV90) [4]
Vinorelbine + Sorafenib DC4ZUON Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + Sorafenib DC3EP5Y Vinorelbine Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + Sorafenib DCIGE1O Vinorelbine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + Sorafenib DCOKHRD Vinorelbine Adenocarcinoma (Cell Line: A427) [5]
Vinorelbine + Sorafenib DCYERPN Vinorelbine Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + Sorafenib DCAYEX9 Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + Sorafenib DC4K0UJ Vinorelbine Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + Sorafenib DC3KA9X Vinorelbine Adenocarcinoma (Cell Line: HCT116) [5]
Vinorelbine + Sorafenib DCVFCP7 Vinorelbine Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + Sorafenib DCTB9FB Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + Sorafenib DCZ55Y7 Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + Sorafenib DC9B535 Vinorelbine Malignant melanoma (Cell Line: A375) [5]
Vinorelbine + Sorafenib DC5QKDA Vinorelbine Malignant melanoma (Cell Line: HT144) [5]
Vinorelbine + Sorafenib DCBGQTG Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + Sorafenib DCR312L Vinorelbine Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + Sorafenib DCXPPNL Vinorelbine Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + Sorafenib DCJ133U Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + Sorafenib DC2UFVD Vinorelbine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinorelbine + Sorafenib DC652Z4 Vinorelbine Prostate carcinoma (Cell Line: VCAP) [5]
Vinorelbine + Sorafenib DCKBTQW Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [5]
Vismodegib + Sorafenib DCXN5DR Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Sorafenib DC8VDBH Vismodegib Renal cell carcinoma (Cell Line: UO-31) [5]
Vorinostat + Sorafenib DCVF73F Vorinostat Adenocarcinoma (Cell Line: CAOV3) [3]
Vorinostat + Sorafenib DCLW1PF Vorinostat Adenocarcinoma (Cell Line: A427) [3]
Vorinostat + Sorafenib DCZEEM7 Vorinostat Adenocarcinoma (Cell Line: NCIH23) [3]
Vorinostat + Sorafenib DCUVTUA Vorinostat Adenocarcinoma (Cell Line: NCIH520) [3]
Vorinostat + Sorafenib DCONX1V Vorinostat Adenocarcinoma (Cell Line: DLD1) [3]
Vorinostat + Sorafenib DCLPY5N Vorinostat Adenocarcinoma (Cell Line: HCT116) [3]
Vorinostat + Sorafenib DCMWJOK Vorinostat Adenocarcinoma (Cell Line: SW-620) [3]
Vorinostat + Sorafenib DCICK1X Vorinostat Amelanotic melanoma (Cell Line: A2058) [3]
Vorinostat + Sorafenib DCCZW7G Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Vorinostat + Sorafenib DCU1ZUQ Vorinostat Germ cell tumour (Cell Line: PA1) [3]
Vorinostat + Sorafenib DCWSQVK Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vorinostat + Sorafenib DCL6RJ0 Vorinostat Malignant melanoma (Cell Line: A375) [3]
Vorinostat + Sorafenib DC2TJG1 Vorinostat Malignant melanoma (Cell Line: HT144) [3]
Vorinostat + Sorafenib DCL7YF6 Vorinostat Malignant melanoma (Cell Line: RPMI7951) [3]
Vorinostat + Sorafenib DCZS2WJ Vorinostat Malignant melanoma (Cell Line: UACC62) [3]
Vorinostat + Sorafenib DCUQKM3 Vorinostat Mesothelioma (Cell Line: MSTO) [3]
Vorinostat + Sorafenib DCYNPD1 Vorinostat Non small cell carcinoma (Cell Line: SKMES1) [3]
Vorinostat + Sorafenib DCKCA7V Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Vorinostat + Sorafenib DCOFHUY Vorinostat Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Vorinostat + Sorafenib DCNNDQ9 Vorinostat Prostate carcinoma (Cell Line: VCAP) [3]
Vorinostat + Sorafenib DCFZD6I Vorinostat Carcinoma (Cell Line: OV90) [4]
Vorinostat + Sorafenib DCLHFAG Vorinostat Colon carcinoma (Cell Line: RKO) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1246 DrugCom(s)

References

1 Sorafenib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.